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                                          INTRODUCTION 
 
                Siddha system of medicine is one of the pristine system of medicine complied 
by Siddhars, who lived a spiritual life in the southern region of India. Siddhars were the 
embodiment of spiritual wisdom, which they served the people not only to cure disease 
but also prevent disease and in turn to increase the life span of human beings. The word 
Siddhi means Endless Knowledge. 
                For one to live long with a healthy body, the 3 fold afflictions of vatham, 
pitham, kabam must be kept under control and in right proportion. When these 3 powers 
(Vali,Azhal,Ayyam) deviates from their natural state due to various causes the disease 
manifest. The five primordial elements produce Mukkutram. 
                               Vali       -Wind + Space  
                               Pitham   -Fire 
                               Kabam   -Earth + Water 
                The 3 powers / humor can be brought to their normal state by taking proper 
food on the basics of 6 tastes 
                Kuzhanthai Maruthuvam is one among glorious branch of siddha system 
which deals with Medical care of Infant, Children, Adolescent and also have hidden an 
enormous treasure for healthy society. 
      Here “ Sooli kanam” is specifically taken for the Dissertation, as it probably 
correlates with childhood Asthma, which is a Respiratory disease encountered by a 
large population of children today and limits their daily activities. 
                 In Balavagadam, the disease are categorized by two factors  
✓ Aga Karana Noigal 
✓ Pura Karana Noigal 
                                      “Ayyam koodir rendraal 
                                       Arivaiyar thuyar thannal”  
INTRODUCTION 
 
                                                                                                                                                                 2 
 
                The Above siddha verse quoted by Ayyodhidhasar, means the SOOLI 
KANAM (Bronchial asthma) occurs due to derangement in Kaba factor. 
                 In Siddha system, according to Balavaagadam, Sooli kanam is compared 
with Bronchial asthma. Sooli kanam is one among the 24 types of Kanam mentioned in 
Balavaagadam but generally Bronchial asthma in Adult is compared with Iraippu noi. 
                Asthma is the most common chronic condition of childhood. Asthma is a 
Diffuse obstructive lung disease or chronic inflammatory disorder of airway due to 
inflammation of airway, increased mucus production, contraction of the Bronchial 
smooth muscle with hyperactivity of the airway to a variety of stimuli. 
                The prevalence and severity of Childhood asthma have increased 
substantially in recent years. Asthma tends to affect about 10% children globally. 
Recent data have shown that Asthma continues to affect 6 million school aged children 
with approximately half of these children experiencing asthma attack each year. 
                In India the mean prevalence was found to be 2.74%. Childhood asthma 
among children 13-14 years of age was lower than the younger children 6-7 years of 
age. 
                In Tamil Nadu at the age of 6-12 years the prevalence ranges from 18% 
                The major determinants of childhood asthma ae still unknown. Familial/ 
Genetic role for etiology is the most important factors. More over Rapid urbanization 
& common environmental triggers such as Air pollution, Allergies, Dust, Weather 
changes, Pets & dander, Mites are the most important predisposing factors for 
childhood asthma. Children are more susceptible to Respiratory disorder due to various 
factors like Poor immunity, Low lung recoil & weak Respiratory muscle. 
               Despite the fact that pediatric Asthma has become an important public health 
problem. It is one of the leading causes for Emergency care requirement & cause for 
considerable morbidity, disability and occasional mortality at all age. If Asthma is not 
treated properly it may lead to impoverished quality of life, repeated attacks which may 
be life threatening, poor growth & limitation of physical activity. 
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    As children are the future of tomorrow, they must get rid of major socio-
economic disease Bronchial Asthma & as a doctor we have responsibility for this. By 
using modern treatment like Nebulizer & inhaler provides temporary relief only, but in 
case of siddha system of medicine we can provide safe treatment without any side effect 
& cost-effective manner.  
   The Ghee based medicine which easily crosses the Blood brain barrier, as well 
as easy absorption in children so I prefer Ghee based medicines as my drug of choice. 
so here I choose KANA NEI a Lipid Based nutritive medicine to enhance immune, safe 
and efficient for the management of sooli Kanam (childhood bronchial asthma) as my 
dissertation topic. 
 




                                     AIM & OBJECTIVE 
AIM: 
The aim of the study is select the cases of  SOOLI KANAM (Childhood Bronchial 
asthma) patients to administrate them with the trial drugs as per the line treatment and 
analysis both clinically and experimentally to prove the safety and efficacy of 
“KANA NEI” for the treatment of  SOOLI KANAM (Childhood Bronchial asthma) 
OBJECTIVES: 
PRIMARY OBJECTIVE: 
To study the therapeutic efficacy of the medicine “KANA NEI” in the treatment of 
SOOLI KANAM (Childhood Bronchial asthma)    
SECONDARY OBJECTIVE: 
The main objective of the present study is to create the knowledge about the siddha 
system and to highlight the efficacy of siddha drugs among people. 
To explore the etiology, clinical features, diagnosis and investigation of Sooli kanam 
through various siddha literature. 
To collect and review the idea mentioned in the primordial siddha literature about the 
disease Sooli kanam. 
To make the comparative study of the siddha and modern aspects of the disease. 
To study the pre – clinical analytical standardization and safety study in the 
experimental formulation of the Kana nei. 
To evaluate the pharmacological study of the trial drug. 
To evaluate the parents and children who were affected by the disease and how to 
stabilize their health through natural way like pranayamam, diet modification and 
personal hygiene. 
To conduct the clinical trial to find out the efficacy of Kana Nei.  
To have a detailed analysis of the disease Sooli Kanam (Childhood Bronchial 
asthma) through efficacy of the drug. 
 




   REVIEW OF LITERATURE 
                                                SIDDHA ASPECT 
இயல்: 
கணம் என்பது கரப்்பசச்ூடு எனக் கூறுவர.் மாந்தத்தின் ததாடர ்நநாநே 
கணமாகும். இது குழவிக்கு, மாந்த நநாே் ஏற்படட்ு முழுவதும் 
குணமாகாமல் உடலில் இருந்நத முற்றி வரும். குழந்ததகள் பாலும் குடித்து 
நசாறும் உண்ணும் பருவத்தில் உண்டாகும் நநாோகும். இது குழந்ததகளது 
மூன்றாமாண்டு முதல் ஏழாமாண்டு வதர துன்பத்ததக் தகாடுக்கும் 
நநாோகும். 
 
ந ோய் வரும் வழி: 
குழந்தத மருத்துவம் (பால வாகடம்) நூல் கணம் நதான்றுவதற்கான 
வழிகதள பின்வருமாறு கூறுகிறது. 
               “ஐயது கூடிற் றறன்றோல் அரிவவயர் துயர ் தன்னோல் 
               றெய்யோற் புனலருத்திெ ்றெறிெல் நதோட ் தன்னோல் 
                 வையர வல்கு லோளும் ைசியுட ிரு ்த தோலும் 
               துய்யநதோர் குழவி கட்குக் கனங்களு ் நதோன்று மன்நறோ”. 
                                                                        -குழ ்வத மருத்துவம் 
 
றைோருள்:  
1.  ஐேமானது தன்னளவின் இருந்து கூடுவதாலும் 
2. அரிதவேரக்்கு (அரிதவேர ் என்பது தபண்களின் பருவங்களின் 
ஒன்றாகும்) 
3. பல்நவறு வதகப்பட்ட நீரிதன பருகுவதால் உண்டாகும் 
சலநதாடத்தாலும். 









2) பிறநூல்களில் கூறை்ைடட்ுள்ள ந ோய்வரும் வழி: 
               கும்பமுனி பாலவாகடம் என்னும் ஏட்டில் கணத்தின் நநாே் வரும் வழி 
பற்றி பின்வருமாறு கூறுகிறது. 
  “தரணிதனிநலயுறு நெயருடலுதனிறல வரு கவணநரோக வரலோறு நகள் 
          கனவுறைறு றகற்ைமில் றரணமது சூடினோல் நைோகமது மிகு சூடினோல் 
   விரவினுடநன ைல நதோெமதினோலினி தோயினுட ைோல் நவவினோல் 
         விள்ளு ைல விெமதோல் தீயினுட கோங்வகயோய்  இளறவயிலு                                                   
                                                                                                றகோள்ளலோலும் 
   உரயுமோகரோமது குவரயுமதினோலினி உண்ணு ைோல் நைதமதினோல் 
          உறமோகநவ கடும் சூடுடநன உண்ணலோல் புளித்த வவக  
                                                                                                  உண்ணலோலும் 
   புவரநமவும் அதிக றைரும் கோரவவக தின்ைதோல் அத்தியது சூடு மிஞ்சி 
         புகழுரிய மோமிெம் கருகியது றரணநம வற்றியதுநவ றயழும்பும்” 
                         -கும்ைமுனி ைோலவோகடம் ைோடல்எண்-451 (ை.எண்:113) 
 
கரப்்பம் தரித்திருக்கும் சமேத்தில் புண் ஏற்படுவதலும், உணவு 
மிகுதிோக உடத்காள்வதாலும், தாே்க்கு ஏற்படும் நதாசங்களாலும், தாே்பால் 
இறுகி கடினப்படட்ு தகாள்வதாலும், தாயிக்கு பால் விடங்கள் ஏற்படுவதாலும், 
உடல் சூட்டினாலும், தவயிலில் திரிவதாலும், உணவு குதறவாக 
உடத்காள்வதாலும், உடத்காள்ளூம் பாலில் ஏற்படும் நபதத்தினாலும், மிகு 
சூடான உணதவ உடத்காள்வதாலும் புளித்த உணவு வதககதள 
உண்ணலாலும், காரவதக உணவுகதள மிகுதிோக தகாள்வதாலும், 









3)“ெரநை ்திர வவத்திய முவறகள்”  கரை்்பிணி ைோலநரோக சிகிெவ்ெ 
பின்வருமோறு கூறுகிறது. 
                 “நதோன்றுமய்ய ைதோரத்்த ் நதோயை்ைவக 
                                 யூன்று தோகம் ைசிமிகு ் துற்றிடில் 
                                 ஏன்ற துன்ைறமல்லோம் வ ்து சூழ்தலோல் 
                                 ஆன்ற நெய்க்குக் கணங்களுமோகுநம”. 
                                           -ெரநை ்திர வவத்திய முவறகள் கர்ை்பிணி ைோலநரோக 
சிகிெவ்ெ (ை.எண்: 57) 
  றைோருள்: 
  மிகுதிோகக் கபத்ததத் விருத்தி தசே்ேக்கூடிே பதாரத்்தங்கதள 
சாப்பிடுவதினாலுன் பசியும் அதிகமாக இருக்தகயில் தண்ணீர ்
அருந்துவதினாலும் பற்பல கணநராகங்கள் குழந்ததகளுக்கு உண்டாகும். 
 
ந ோய் நதோன்றும் வயது: 
கணம் நதான்றும் வேது பற்றி பல்நவறு கருத்துகள் உள்ளன. கணம் 
குழந்ததகள் பாலும் குடித்து நசாறும் உண்ணும் பருவத்தில் வரும் நநாோகும். 
இது குழந்ததயின் மூன்றாமாண்டு முதல் ஏழாமாண்டு வதர வரும் நநாே் 
என்பதத, 
 
                                         “என்னநவ கணோ மூன்று வருட ் றதோட்நட 
                                           ஏழோண்டு மட்டுக்கு மிருக்குங்கோலம்” 
                                                                                                              -ைோலவோகடம். 










4)“தன்வ ்திரி வவத்தியம்” என்னும் நூலில் பின்வருமோறு 
கூறை்ைடுகிறது. 
                        “சீரிய றதோன்வம றெய்த தீவிவன த ்வதயோகை் 
                          ைோரிலிை் பிறை்பிற் றெய்த ைோவநம தோயோகை் 
                          நைரிய ெயக் குமரன் விற ்திலோ கிறமத்தை்நை 
                          கோரிய றெவிலித் தோயோய் கணம் றைற வளரும் ோளில்” 
- தன்வ ்திரி வவத்தியம் 
றைோருள்: 
முற்பிறவியில் தசே்த தீவிதனகள் தந்ததோகவும் இப்பிறவியில் தசே்த 
தீவிதனகள் தாோகவும் தகாண்டு குமாரனாகிே கணம் நதான்றுகிறது. 
 
5)திருவள்ளுவ  ோயனோர் இயற்றிய  வரத்தின சி ்தோமணி-800 
என்னும் நூலில் பின்வருமோறு கூறை்ைடுகிறது. 
                            “ைோரோன றகற்ைறவட்வட மீரும் ைக்குவத்தில் 
                              நவரோன் வி ்து றவளி ைட்டு நயோளி விழு ்த றதன்றோற் 
                              கோரோன் பிண்டங் கனலிலடி ைட்டுக் கோ ்தியினோற் 
                              கூரோய் கனசுர றமய்து றமன்நறயோன் கூறிநனநம”. 
றைோருள்:  
தகற்பதவடத்ட மீறியிருக்கும் நநரத்தில் கருவுற்றிரிக்கும் 










6) ைரரோெ நெகரம் என்னும் நூலில் ைோலநரோக  ிதோன ைடலத்தில் 
கணம் குழ ்வதகளின் 12 வயது வவரயிலும் கோணும் ந ோய் என 
கூறுகிறது. 
அதாவது 
                 “என்ற நதோர் கவண கடோமுமிை்ைடி றயழு ்து றைோங்கி 
                   ின்ற நைர் ைதிறனட்டு தோனிவற ்திரு மோண்டின் நமலோய்க் 
                   கன்றிய ைோலர் றமய்யிற் ைன்னிரண்டோண்டு கோறும் 
                   ின்றிடு றமன்று முண்ணோணிகழ்த்தினன் முனிவனன்நற”.  
                                                               - ைரரோெ நெகரம் (ைோலநரோக ிதோனம்) 
 
ைோலவோகடம் நூலில் கீழ்கோணுமோறு கூறை்ைடுகிறது. 
                  “மலமுஞ் ெலமு மிகத் தீய் ்து மோர்பிலதிக சுரங்கோயும் 
                    மலமும் வயிறு மிக றவரியும் வளமோய் தவலயு மிக மயக்கும் 
                    ெலமும் வரள் தீ தோன் குவறயும் ெண்டோளம் நைோலுட் சுரமோம் 
                    தலநம ைன்னிரண்டோண்டு மட்டும் தனதோய் வருங் குணமிதுநவ”. 
- ைோலவோகடம் 
எனநவ, கணமானது குழந்தத பிறந்தது முதல் 12 ஆண்டு வதர நதான்றும் 
நநாே் எனவும் தகாள்ளலாம். 
 
கர்ை்ைெ ்சூடு: (3 முதல் 7 வயது வவர) 
         “றதோவகயோன் கணங்கள் எல்லோம்  கர்ை்ைெச்ூடு”. 
                                                    -அநயோத்திதோெர் ைோலவோகடம். 
கரப்்பசச்ூடு  என்பதில் சூடு என்பது அழல் தாதுதவ குறிப்பதாகும். அகத்திேர ்
வல்லாதி நாடி நூலில் கருதவ காப்பதில் அழல் தாதுவின் முக்கிேத்துவத்ததப் 
பற்றி கீழ்கண்டவாறு கூறப்படுகிறது .  
           




            “ைோண்வம என்ற வி ்தங்நக ஊறும் நைோது 
                             ைோயுமை்ைோ வன்னிநயோடு வோயு ் தோநன” 
                                                 -அகத்தியர் வல்லோதி ோடி நூல் 
விந்து சுநராணிதத்நதாடு நசரத்்து கருவுறுதுலுக்கு துதண புரிவது 
வாயு(வாதம்) ஆகும். அவ்வாறு உற்பத்திோன் கருதவ காத்து வளர தசே்வது 
அழல் தாதுவாகும். 
    “வன்னியும் வோயுவு மோயிரு ் சுக்கிலம்” 
- திரும ்திரம் 
ந ோய் ஏற்ைட கோரணங்கள்: 
     அழல் தாதுவும் வளிதாதுவும் சுக்கிலத்துடன் நசரந்்நத இருக்கும் என 
திருமந்திரம் நூலில் கூறப்படுகிறது. 
இவ்விரு நூல்களின் கூற்றுபடி சுக்கிலத்துடன் அழல் தாது உள்ளது என 
அறிேலாம். இவ்வாறு சுக்கிலத்துடன் கூடிே அழல் தாது தன்னளவில் 
மிகுதிபடுவதால் சுக்கிலத்துடன் விகற்பம் ஏற்படட்ு கருவின் அழல் தாது 
மாறுபடுகிறது. இதனால் கருவிற்கு சூடு அதிகமாகிறது. இததனநே 
“கரப்்பசச்ூடு” எனக் தகாள்ளலாம். 
 
மோ ்தத்தின் றதோடர் ந ோநய கணமோகும்: 
▪ மாந்த நநாே் ஏற்படட்ு முழுவதும் குணமாகாமல் உடலில் இருந்நத முற்றி  
வரும். 
▪ மாந்தம் என்பது உருவ நிதலயில் உடல் நிதலயில் மந்தம், அதாவது 
தாயின் உணவு பழக்கங்களால் குற்றங்கள் நகடதடயும் நபாது 
குழந்ததகளுக்கு நதான்றும் நகாளாறுகள் மாந்த நநாே் ஆகும். 
▪ மாந்தம் ததாடந்து நிதலப்பதால் உணவின் சாரம் உடற்கடட்ுகளுக்கு 
நசரவ்தில் ததடகள் ஏற்படுகிறது. 
▪ சாரம் தசந்நீராக மாறும் தன்தம பாதிக்கப்படுகிறது. 
▪ மற்ற உடற்கடட்ுகள் நபாடணிக்கப்படிவதில் பாதிப்பு 
▪ உடற்கடட்ுகளின் வன்தம குதறகிறது. 
▪ கணத்தின் குறிகுணங்கள் நதான்றுகிறது. 




வயதிவன றைோறுத்து:  
 கணம் நதான்றும் வேதுப்பற்றி பின்வரும் வரிகளில் அறிேலாம், 
                          “என்னநவ கணமூன்று வருட ் றதோட்நட 
                            ஏழோண்டு மட்டுக்கு மிருக்குங்கோலம்” 
- ைோலவோகடம் 
என்ற பாடலினால் மூன்று ஆண்டு முதல் ஏழு ஆண்டு வதர வரும் நநாே் 
என்பதத அறிேலாம் 
கணத்தின் வவககள்: 
    பல நூல்களில்   பலவதககளில் கணம்  வதகப்படுத்தப்படட்ு இருக்கிறது 
1)ைோலவோகடம் நூலில் 24 வவகயோக கூறை்ைடுகிறது 
 
                        “கணங்கட்நைர் விரித்தவறக் நகள் ண் றோகக் 
                          கனவோத கணம்பித்த கணங் குளிர் ்த 
                          மணமோன நெத்மகணம் பிள்வள கட்கு 
                          மோ ்தகணம் அதிற்பிரிவு ஐ ்தோம் இை்ைோல் 
                          துணமோ ீரக்் கணம்பிரளிக் கணமு ல்ல 
                          சூலிகணஞ் சுழிகண மகோ கண ்தோன் 
                          குணமோன ஊதுகணம் வரட்கண ்தோன் 
                          றகோதிை்புகணம் வீக்ககணம் இன்னங் நகநள 
                          நகநள ீ  பிறக்கணமும் அ ்த கன்தன் 
                          கணமும்ம ் தோரகணம் எரிக ண ்தோன் 
                          முநள ீ ரோமகணம் ஆமகண றமத்த 
                          முக்குகணம் மூலகணம் நைரோ மத்தின் 
                          வோநளசிங் கிநயோடிரத்த கணமோம் எல்லோம் 
                          வருத்துவரத்த திருைஃது ோங்கு மோகக் 




                          நகோநளது இவவதோநன மருத்து நூலின் 
                          குறிை்ைறி ்தோரக்் கல்லோமல் மற்நறோரக்் நகநத” 
-ைோலவோகடம். 
 
1. வளி கணம்                                                         13. வீக்கக் கணம்                                               
2. அழல் கணம்                                                      14. பிறக் கணம்  
3. ஐே கணம்                                                          15. அந்தகக் கணம் 
4. மாந்த கணம்                                                     16. மந்தார கணம் 
5. நீரக்் கணம்                                                         17. எரி கணம் 
6. பிரளிக் கணம்                                                   18. நீராம கணம் 
7. சூலி கணம்                                                         19. ஆம கணம் 
8. சுழி கணம்                                                          20. முக்கு கணம் 
9. மகா கணம்                                                        21. மூல கணம் 
10. ஊது கணம்                                                      22. நபராம கணம் 
11. வரள் கணம்                                                     23. ரதத் கணம் 
12. தகாதிப்பு கணம்                                           24. சிங்கி மாந்த கணம் 
 
2) ஆத்ம ரடெ்ோமிரத்ம் எனும் வவத்திய ெோர ெங்கிரம் என்னும் நூலில் 
பின்வருமோறு கூறை்ைடுகிறது. 
               “ைோரை்ைோ கணவகுை்பு ைதிறனட்டோகும்  
                     ைோடினோர் வோதகணம் பித்தகணநமோடு 
                ந ரை்ைோ நெத்மகணம் மோ ்தகணமின்னம் 
                     ீ ரக்்கணஞ் சூவலக்கணம் பிரளிகண ்தோன் 
                ெோரை்ைோ ஊதுகணம் சுழிகண ்தோன் 
                     ெோரவ்ோன மோகணமும் வரட்கண ்தோன் 




                கூரை்ைோ றகோதிை்புகணம் பிறக்கண ்தோன் 
                     குறிை்ைறிவோவயவய ்து கணமுமோநம” 
                                                          -ஆத்மரட்ெோமிரத்ம். 
 
மாந்த முதிரந்்து, 
1) வாத கணம்                                                   14) வீக்க கணம் 
2) பித்த கணம்                                                  15) ஆமக் கணம் 
3) நசத்ம கணம்                                               16) நததரக் கணம் 
4) மாந்த கணம்                                               17) முக்கு கணம் 
5) நீரக்் கணம்                                                   18) மூலக் கணம் 
6) சூதலக் கணம்                                            19) நபாரக்் கணம் 
7) பிரளிக் கணம்                                             20) இரத்தக் கணம் 
8) ஊது கணம்                                                  21) விமாந்த கணம் 
9) சுழி கணம்                                                    22) ஊது மாந்த கணம் 
10)  மா கணம்                                                    23) அந்தக் கணம் 
11)  வரட் கணம்                                                 24) மந்தார கணம் 
12)  தகாதிப்பு கணம்                                       25) எரி கணம் 
13) பிறக் கணம் 
என கணங்கள் 25 வதகப்படும் 
 
3) கும்ைமுனி ைோலவோகடம் எனும் நூல் கணத்வத 18 வவகயோக 
கூறுகிறது. 
  “மோது கனிநவோடினி நகளும் றரோன்ைதில் நைரு வவகயோனதி ீ  
         மருவு சுரநமோடினி தூங்குகவண றரத்தமும் வறட்வெநயோடு றவை்பு 
கவணயும் 
    நைோதநமோடு வீங்கலும் அனல்கவண மோ ்தமும் மஞ்ெளும் ீ லமதுவும் 
          றைோங்கிடும் ெரத்்திநயோடு ரத்தமும் நமகமுடநன வோநல ்திரன் 
வோவல ெ ்திரன் 




    நமோதுமினி அத்தியின் சுரக்கவன மநக ்திர உள்ளுறரோகம் 
றையரிவவகள் 
          முவறயோகநவ யிவவ வவகய றதோன்று நமலதோய் ஈரோறு வயது மட்டும் 
     நகோதகலு ைோலவர வோவதயது றெய்யும்றம குணநமோடவு ெதங்கள் 
           கூறோகநவயினி நமலோலுவரக்கிநறன் ஒவ்றவோன்றும் ஊன்றி அறிநய” 
                              -கும்ைமுனி ைோலவகடம் ைோடல் எண்:452(ை.எண் :114) 
அதவகள்: 
1) சுரக்கதண                                                  10) நீலக் கதண 
2) தூங்கு கதண                                             11) சத்திக் கதண 
3) மூலதரத்தக் கதண                                 12) தரத்தக் கதண 
4) வறடத்சக் கதண                                    13) நமக க் கதண 
5) தவப்பு கதண                                            14) அத்திசச்ுர கதண 
6) அனல் கதண                                             15) வநலந்திரக் கதண 
7) வீங்கு கதண                                              16) வால சந்திர கதண 
8) மாந்தக் கதண                                          17) மநகந்திரக் கதண 
9) மஞ்சள் கதண                                              18) உள்ளு நராகக் கதண 
 




          “உரறமனுற கவணகண் முன்நனருவரத்தோவறுவரை்ைடக் நகண்மின் 
       “சுரறமனுற் கவணயுறமோன்று துங்குமக் கவணயுறமோன்று 
             ிரவிய மூல மிரத்த ீ ங்கரும் வரட்சி றவை்புக் 
       கருவுறு மனலன் வீங்கி கூடியநதோர் மஞ்ெ ணீலன் 
             ீ லமோங் கணோய்யிநனடு ின்றிடு றவளுை்பு மோகும் 
       ெோலநவ ெத்தி நமலி ் தை்பிலோ மோ ்தோ நமகம் 




             நமலதோம் விவனகள் நைோல மிரு ்திடுற் கழிெெ்ல் கோெம் 
       ஆலமோரிரும றவய்ை்பு மோவிவவ ைதிறனட்டோநம”   
                                                                              -ைரரோெநெகரம் 
 
1) வாத கதண                                             10) வீங்கு கதண 
2) பித்த கதண                                            11) தவளுப்பு கதண 
3) சுரக் கதண                                             12) சத்தி கதண 
4) அத்திசுர கதண                                    13) இரத்த கதண 
5) வரட் கதண                                             14) மூலக் கதண 
6) வாலசந்திர                                               15) கருங் கதண 
7) மநகந்திர கதண                                  16) மஞ்சட் கதண 
8) தூக்கு கதண                                          17) நிலக் கதண 
9) அனற் கதண                                          18) தவப்பு கதண 
 
5.ஜீவரடெ்ோமிரத்ம் எனும் நூல்-8 வவகயோக் கூறுகிறது 
          1) சூலி கணம்                                                 5) மகா கணம் 
          2) முக்கு கணம்                                              6) சுழி கணம் 
         3) ஆம கணம்                                                   7) கழி கணம் 
         4) நததர கணம்                                              8) வரள் கணம் 
 
6)அநயோத்திதோெர ் ைோலவோகடம் நூலில் 24 வவகயோக 
கூறை்ைடுகிறது. 
அதவகள்: 
1) வளி கணம்                                            13) வீக்க கணம் 
2) அழற் கணம்                                          14) பிறக் கணம் 
3) ஐே கணம்                                              15) அந்தக் கணம் 
4) மாந்த கணம்                                         16) மந்தார கணம் 
5) நீரக்் கணம்                                             17) எரி கணம் 




6) பிரளி கணம்                                          18) நீராம கணம் 
7) சூலி கணம்                                             19) ஆம கணம் 
8) சுழி கணம்                                              20) முக்கு கணம் 
9) மகா கணம்                                            21) மூல கணம் 
10) ஊது கணம்                                            22) நபராம கணம் 
11) வரள் கணம்                                           23) ரத்த கணம் 
12) தகாதிப்பு கணம்                                 24) சிங்கி மாந்த கணம் 
 
7) ெரநை ்திர வவத்திய முவறகள் கர்ை்பிணி ைோலநரோகசிகிெவ்ெ 
என்னும் நூல் கூறும் வவககள் 
1) நீரக்் கணம் 
2) வரட் கணம் 
3) எரி கணம் 
4) சுழி கணம் 
5) மூல கணம் 
6) முக்கு கணம் 
7) விக் கணம் 
8) ஆம கணம் 
9) நீரக்் கணம் 
10) வரட் கணம் 
11) எரி கணம் 
12) சுழி கணம் 
13) மூல கணம் 
14) முக்கு கணம் 
15) விக் கணம் 
16) ஆம கணம் 








8) தன்வ ்திரி வவத்தியம் ெயநரோக  ிதோனம் என்னும் நூலின் ைடி 8 
வவகயோக கூறை்ைடுகிறது. 
அதவகள்: 
1) வால சேம் 
2) வீர சேம் 
3) தருண சேம் 
4) கணிக சேம் 
 
9)ஆவியளிக்கும் அமுத முவறெ ்சுருக்கம் எனும் நூல் 23 வவகயோக 
கூறுகிறது. 
அதவகள்: 
1) வாத கணம்                                                     13) வீக்க கணம் 
2) பித்த கணம்                                                   14) பிறக் கணம் 
3) சிநலத்தும கணம்                                         15) ஆமக் கணம் 
4) மாந்த கணம்                                                  16) வரள் கணம் 
5) நீரக்் கணம்                                                      17) முக்கு கணம் 
6) பிரளி கணம்                                                   18) நபாரக்் கணம் 
7) சூதல கணம்                                                  19) இரத்தக் கணம் 
8) சுழி கணம்                                                       20) நசச்ு மாந்த கணம் 
9) மகா கணம்                                                      21) ஊது மாந்த கணம் 
10) ஊது கணம்                                                      22) எரி கணம் 
11) வறட்சி கணம்                                                 23) மந்தார கணம் 
12) தகாதிப்பு கணம்    
 
                                “தோனோன் நதவர கணம் முக்கு கண ்தோன் 
                                       தனியோன மூல கணம் நைோர் கண ்தோன் 
                                  ஊணோன் ரத்த கணம் விடோ மோ ்த கணமும் 
                                       ஊது மோ ்தக் கணமோம் மோ ்த கண ்தோனும் 
                                  நகோனோன ம ்தோர கணமு ் தோனும் 




                                       கூரோன எரிகணமோ மிருைத்து மூன்றும் 
                                   ைோனோன கணங்கள் ைன்னிரண்டு ைகர் ்ததோநம” 
                                                     -ஆவியளிக்கும் அமுத முவறெ ்சுருக்கம் 
 
10)பிள்வளை்பிணி வோகடம் எனும் நூல் 8 வவகயோக கூறுகிறது. 
       1) வரள் கணம்                                                5) மகா கணம் 
       2) மூல கணம்                                                 6) மலக் கணக் 
       3) சீத கணம்                                                    7) குண்டலிே கணம் 
       4) இதே கணம்                                               8) நீர ்கணம் 
என கணத்தின் வதககள் கூறப்படட்ுள்ளன 
முக்குற்ற நவறுைோடு: 
          உணவாதி தசேல், அக, புற காரணங்களால் ஏற்படும் சுக்கில சுநராணித 
நதாடங்களின் நவறுபாடுகளாலும் விந்துவுடன் உடத்சல்லும் பிராணன், 
தவளியிலிருந்து காக்கும் அபானன், கருதவ வளரக்்கும் உதானன் ஆகிே 
வாயுக்கள் பாதிப்பதடந்து அழல் குற்றம் மிகுதிபடட்ு கரப்்பசச்ூடு 
உண்டாகிறது. மிகுதிபட்ட அழலானது கபத்தின் இருப்பிடமான மாரப்ு 
பகுதிதே பற்றி தகாண்டு கபத்தத வளரச்ச்ி தபற தசே்து கணத்தின் 
குறிகுணங்கதள உண்டாக்குகிறது. 
சூலி கணம்: 
         குழந்ததகளுக்கு உண்டாகும் கதணயின் ஒரு வதக சூலி கணம் ஆகும். 
சூலி கணம் -விளக்கம்: (ைோலவோகடம்) 
கரப்்பத்திநலற்பட்ட கணசச்ூட்டினால் குழந்ததகளுக்குண்டாம் ஓர ்நமல்மூசச்ு 








சூலி கணம் – குறிகுணங்கள் : 
                    “உண்டோஞ் சூலி கணங்நகளோய் 
                      உற்ற சுவோெ நமநலலு ம்பிபித் 
                      தண்டோ இருமல் மிக உண்டோம் 
                       றதோண்வட ோவு நமவ ்து 
                       நெோரும் றைோருமி வயிற்றுை்பும் 
                       வண்டோர் முவலயுங் குடியோது 
                       வவகயோய் முகமும் ோறுமன்நற” 
                                                             -ைோலவோகடம் , ை.எண்.294 
றைோருள்: 
➢ நமல் மூசச்ு உண்டாதல் 
➢ இருமல் அதிகமாக ஏற்படுதல் 
➢ தநஞ்சு, வாே், ததாண்தட நாக்கு தவந்து புண்ணாதல் 
➢ வயிற்றுப் தபாருமல் உண்டாதல் 
➢ தாே்ப்பால் உண்ண சிரமம் 
➢ முகத்தில் நாற்றமடிக்கும் என்று பாலவாகடம் நூலில் கூறப்படட்ுள்ளது. 
 
           ற ஞ்சு வோய் றதோண்வட ோவு 
           ந ருறு றவ ்து புண்ணோய் 
           துஞ்ெல்தன் முவலயுண்ணோது 
           சுவோெநமோ டிரும லுண்டோம் 
           தஞ்ெமோய் வயிறு றைோருமித் 
           தோய்முவல யுண்நடோட் டோது 
           கஞ்ெவல முகமும் ோறும் 
           கணசூலிக் கணமி தோநம” 
 




                      “உடலது றவளுத்து ோவும் 
          உதடுக றளயிறும் றவ ்து 
          திடமுடன் முவலயுண்ணோது 
           சிவ ்து ீ றரரி ்து வீழும் 
           அடர்ம லம்பிசின் நைோலோ 
           தல்லது நுவரத்து வீழ்தல் 
           ைடரச்ுரம் வயிற்று லுண்டோம் 
           ைகரற்கர்ை்ை கணம தோநன” 
                                         -பிள்வளபிணி மருத்துவம்,ைோகம்-2, ை,எண்-334 
றைோருள்: 
➢ தநஞ்சு, ததாண்தட, நா புண்ணாதல் 
➢ தாே்ப்பால் உண்ணாதம 
➢ சுவாசம், இருமல் 
➢ வயிறு தபாருமல் 
➢ முகம் நாறுதல் 
➢ உடல் தவளுத்தல் 
➢ உதடு வயிறு புண்ணாதல் 
➢ நீர ்எரிசச்ல் 
➢ மலசச்ிக்கல் 
➢ வயிற்றில் சுரம் காே்தல் என்று பிள்தள பிணி மருத்துவம் நூலில் 
கூறப்படட்ுள்ளது. 
                         
                                     சூலிகணநரோகம் 
நமல்மூசச்ு, இருமல், தநஞ்சு நாவும் நாபியும் புண் நபாலிருத்தல், 
பாலுண்ணாதம, முகநாற்றம் என்னும் இக்குணங்கதள உண்டாக்கும் என்று 
ஜீவரடச்ாமிரத்ம் சிறப்பாயிரம் நூலில் சூலிகணநராகம் என்ற ததலப்பில் 
கூறப்படட்ுள்ளது. 
-ஜீவரடச்ாமிரத்ம் ப.எண்:288 





ந ோய் கணிை்பு (DIAGNOSIS): 
சித்த மருத்துவம் ந ோய்கணிை்பு: 
• பிணிேறி முதறதம 
• உயிர ்தாதுக்கள் (முக்குற்றம்) 
• உடல் தாதுக்கள் (ஏழு உடற்கடட்ுக்ள்) 
• பருவகாலங்கள் 
• ஐவதக நதரவ்ு 




• நமற்கூறிே காரணிகளின் மாறுபாடுகதள ஒன்றுடன் ஒன்று 
ஒப்பிடட்ு நநாே் கணிக்கப்படுகிறது. 
பிணியறிமுவறவம: 
1. தபாறிோல் அறிதல் 
2. புலனால் அறிதல் 
3. வினாதல் 
சூலிகணத்தில் ந ோயோளிக்கு கோணும் குறிகுணம்: 
1.றைோறியோல் அறிதல்: 
         மூக்கு - மூக்கு நீரப்ாே்தல் 
          நா       - நகாதழ நுதரதல் 
          கண்   - சிலநவதல கண்சிவத்தல் 
          காது   - இேல்பு 
          நதால் – சிலநவதல அரிப்பு தடிப்பு காணல் 
 
2.புலனோல் அறிதல்: 
         ஊறு       - தவப்பம் 
          ஓதச      - இேல்பு 
          ஒளி         - இேல்பு 




          சுதவ      - இனிப்பு சுதவ ததரிதல் 
          நாற்றம்  - மூக்கில் சளி சவ்வு தடிப்புறுதல் 
 
3.வினோதல் : (நகடட்றிதல்) 
               மருத்துவன் தன்தன நநாக்கி வந்த பிணியுற்றவதனப் பற்றி அறிே 
நவண்டிேவற்தற அறிந்தும், தன் தபாறி புலங்களால் நநாோளியின் தபாறி 
புலன் வழிோே் உணரவ்தத நநாோளியினிடத்நத (அ) அவன் தபற்நறார ்
சுற்றத்தாதரக் தகாண்நடா அவனது தபேர,் வேது, திதண, குடும்ப 
வரலாறு, உணவு பழக்கவழக்கம், முந்ததே நநாயின் வரலாறு, ஒவ்வாதம 
வரலாறு நபான்றவற்தற அறிதல் ஆகும். 
உயிரத்ோதுக்கள்: 
1. வோதம்: 
சூலிக்கணத்தில் கோணை்ைடும் வோதத்தின் ிவல: 
 1.பிராணன்   - பாதிப்பு (மூசச்ுவிடல், வாங்கலில் சிரமம்) 
 2.அபானன்  -பாதிப்பு(மலசச்ிக்கல், உடல் வன்தம குதறதல்) 
 3.விோனன்  - பாதிப்பு (உடல் குன்றுதல்) 
 4.சமானன   - பாதிப்பு (பிற வாயுக்கதள கடட்ுப்படித்துவதில் 
 சிரமம் 
 5.உதானன் -பாதிப்பு (இருமல்,வாந்தி,நமல்மூசச்ு, நபசத்சாலி குதறதல் 
உடல் நசாரவ்ு) 
 6.நாகன்        - பாதிப்பு ( படித்தல், விதளோடல் நபான்ற  
 தசேல்கதள தசே்ே சிரமம்) 
 7.கூரம்ன்       - இேல்பு 
 8.கிருகரன்    - பாதிப்பு (வாயில் நகாதழ நுதரதல், இருமல், மூக்கு நீர ்
பாே்தல், பசியின்தம ) 
 9.நதவதத்தன் - பாதிப்பு (ஸில நவதள மிகுந்த அசதி காணல்) 
 10.தனஞ்தசேன். 





சூலிக்கணத்தில் பித்தத்தின் ிவல: 
1.அனற்பித்தம்     - பாதிப்பு (பசியின்தம, தசரிோதம ) 
 2.இரஞ்சகபித்தம் - பாதிப்பு ( உடல் தவளுப்பு ) 
 3.சாதகப்பித்தம் -பாதிப்பு (அன்றாட நவதலகதள தசே்வதில் சிரமம்) 
 4.பிராசகம் – சில நவதல பாதிப்பு (நதாலில் அரிப்பு) 
 5.ஆநலாசகம் – இேல்பு 
3.கைம்: 
சூலிகணத்தின் கைத்தின் ிவல: 
 1.அவலம்பகம்   -  பாதிப்பு (மூசச்ு விட சிரமம்) 
 2.கிநலதகம்    - பாதிப்பு (தசரிோதம) 
 3.நபாதகம்      - இேல்பு  
 4.தற்பகம்        - சில நவதள பாதிப்பு (கண் சிவத்தல்) 
 5.சந்திகம்        - இேல்பு 
உடற்கட்டுகள்: 
சூலிகணத்தில் உடற்கட்டுகளின் ிவல: 
 1.சாரம்      - பாதிப்பு (உடல் நசாரவ்ு, உடல்குன்றல்) 
 2.தசந்நீர ்  - பாதிப்பு (உடல் தவளுப்பு) 
 3.ஊண்      - பாதிப்பு (உடல் இதளப்பு) 
 4.தகாழுப்பு - இேல்பு 
 5.என்பு       - இேல்பு 
 6.மூதள    - இேல்பு 
 7.தவண்ணீர/் சுநராணிதம் 
 





 1.காரக்ாலம்    - ஆவணி, புரட்டாசி ( Aug, Sep ) 
 2.கூதிரக்ாலம்  - ஐப்பசி, காரத்்திதக ( Oct, Nov ) 
 3.முன்பனி       - மாரக்ழி, தத ( Dec, Jan ) 
 4.பின்பனி        - மாசி, பங்குனி ( Feb, Mar ) 
 5.இளநவனில் - சித்திதர, தவகாசி ( Apr, May ) 
 6.முதுநவனில்  - ஆனி, ஆடி ( Jun, July ) 
 
முக்குற்றங்களும் ைருவகோலங்களும்: 
வ.எண் ைருவகோலங்கள் குற்றங்கள் குற்றத்தின் ிவல 







தன்னிதல வளரச்ச்ி  








3  முன்பனிகாலம் பித்தம் 
 
தன்னிதல வளரச்ச்ி 
4 பின்பனிகாலம் கபம் தன்னிதல வளரச்ச்ி 
 
5 இளநவனில்காலம் கபம் நவற்றுநிதல வளரச்ச்ி 
6 முதுநவனில்காலம் 
 









            சூலிகணத்தில் பித்தநதாடம் பாதிப்பதடந்து தன்னிதல வளரச்ச்ி 
அதடந்து பின்னர ் வளிகுற்றம் நவற்றுநிதல வளரச்ச்ி அதடந்து அதன்பின் 
கபமானது தன்னிதல வளரச்ச்ி அதடந்து சூலிகணத்தின் குறிகுணங்கள் 
நதாற்றிவிக்கின்றன.  
          எனநவ காரக்ாலம் முதல் பின்பினி காலம் வதரயுள்ள காலம் சூலிகணம் 
நதான்றுவதற்குரிே காலங்களாக்கும் ( Sep to March ) 
 
ஐவவக ிலங்கள்: 
 1.குறிஞ்சி (மதலயும் மதல சாரந்்த இடமும்)- சிநலத்துமம் தங்கும் 
 2.முல்தல (காடும் காடு சாரந்்த இடமும்) – வல்தல வாத நநாே் 
உண்டாக்கும். 
 3.மருதம் (வேலும் வேல் சாரந்்த இடமும்) – முத்நதாட நநாே்கதள 
ஒழிக்கும்.  
 4.தநே்தல் (கடலும் கடல் சாரந்்த இடமும்) – வாத நநாே் குடல் வாயு 
உண்டாக்கும் 
 5.பாதல (மணலும் மணல் சாரந்்த இடமும்) – முத்நதாட நநாே்களுக்கு 
இருப்பிடம். 
 
எண்வவகத்  நதரவ்ு: 
  “ ோடி ைரிெம் ோ ிறம் றமோழிவிழி 
   மலம் மூத்திரமிவவ மருத்துவரோயுதம்” 
 
சூலிகணத்தின் எண்வவக நதரவ்ின் ிவல: 
 1.நா – மஞ்சள் (அ) பசத்ச மஞ்சள் நிறம் 
 2.நிறம் – நதால், கண், நா, நகம் தவளுத்தல் 
 3.தமாழி – குரல் ஒலி தாழ்தன் 




 4.விழி – சிலநவதள கண் சிவத்தல், தவளுப்பு, கண் அரிப்பு காணல். 
 5.மலம் – மலக்கடட்ு 
 6.மூத்திரம் – தவண்தம கலந்த மஞ்சள் நிறத்துடன் நுதர காணல் 
 7.ஸ்பரிசம் – சிலநவதள சுரம் இருந்தால் மிகு தவப்பமாகவும் 
சிலநவதள தட்பமாகவும், விேரத்வயும் காணும். 
 8.நாடி – வாத கபம், பித்த கபம், வாத பித்தம். 
 
 ீரக்்குறி: 
 “அரு ்து மோறிரதமும் அவிநரோதமதோய் 
  அக்கல் அலரத்ல் அகோலவூன் தவிர் ்தழற் 
  குற்றளவருத்தி உறங்கி வவகவற 
  ஆடிக்கலெத் தோவிநய கோதுறைய் 
 றதோரு முகூரத்்தக் கவலக்குட்ைடு ீ ரின் 
 ீரக்்குறி ற ய்க்குறி ிருமித்தல் கடநன” 
 
விளக்கம்: 
 நீரக்்குறி பாரக்்கும் முதல் நாள் இரவு நன்கு உணவு உண்ண நவண்டும். 
பின் விடிேற்காதல படிகபாத்திரத்தில் நீரிதன பிடித்து அதன் நீரக்்குறி மற்றும் 
நிறக்குறியிதன கண்டறிதல் நவண்டும். 
                         “வ ்த ீ ர் கரிறயவட மணம் நுவர ஏஞ்ெறலன் 
              வற ்தியலுளவவவ யவரகுது முவறநய” 
-ந ோய் ோடல் முதல் ைோகம் 
நீரில் நிறம் மணம் நுதர, எதட எஞ்சல் இவற்தற காண நவண்டும். 
 
 





                “ ீரக்்குறி குவரத்த ிருமோன ீ ரிற் 
                  சிறக்க றவண்றனய்நயோர் சிறுதுளி டுவிடுத் 
                  றதன்னுறத் திற ்தறவளி நயோகோ தவம ்ததி 
                  ின்றதிவவல றைோம் ற றிவிழியறிவும் 
                                சிறு ீரில் ல்றலண்றணய் விட்டு ைோர்ை்ைது”. 
விளக்கம்: 
       கணநநாோளின் சிறுநீதர நசாததன வட்டிலில் ஊற்றி, சூரிே ஒளி மிகுந்த 
இடத்தில் நீரின் அதலயில்லாத நபாது நல்தலண்தணே்த்துளி விடட்ு பாரப்்பது. 
                               “அரறவன ீ ண்டில் வோதம் 
                                 ஆழிநைோற் ைரவின் பித்தம் 
                                 முத்றதோத்து ிற்கின் கைம்” 
அரவு (பாம்பு) நபால் பரவினால் வாத நீர ்ஆழி (நமாதிரம்) நபால் பரவினால் 
பித்த நீர ்முத்து நபால் பரவினால் கப நீர ்ஆகும். 
 
 ோடி: 
சூலிகணத்தில் ெதக ோடி வட: 
வோத பித்த ோடி: 
 “றைோருளோன வோதத்தில் பித்தஞ் நெர் ்து 
  றைோருத்து குணங்களோ முஷ்ணவோயு ெத்தி 
  றெரியோவம புளித்நதை்ைம் றைோருமல் ீ ரிற் 
  சிவை்பு மலம் பிடித்தலுரு ் தோது ட்டம் 
  கருவோன நதகமதி லுவளெெ்ல் நெோம்ைல்” 
 
 




வோத கை ோடி: 
 “ைோங்கோன வோதத்தில் நெத்தும ோடிை் 
   ைரிசித்தோல் திமிர்நமவு முவளெெ்லோகும் 
   தீங்கோன இருமலுடன் ெ ்தி நதோடம் 
   வோங்கோத ஈவளம ் தோர கோெம் 
   வலியுடநன புறவீெச்ு உள்வீெச்ு 
   ஓங்கோணுஞ் சுரமுடநன சுவோெகோெம் 
   உண்டோக்கும் றவகுந ோய்க்கு முறுதி தோநன” 
                                                                                   -ெதக ோடி 
மருத்துவம்: 
         “ந ோய் ோடி ந ோய் முதல் ோடி அது தணிக்கும் 
           வோய் ோடி வோய்ை்ைெ ்றெயல்” 
“நநாே்நாடல், நநாே்முதனாடல்” இவ்விரண்டும் பிணிதே அறிவதற்க்கு 
இன்றிேதமோதது பற்றியும், அதன் பிறகுதான் மருந்ததக் குறிப்பிடல் 
நவண்டும். 
         “உற்றோன ளவும் பிணியளவுங் கோலமும் 
           கற்றோன் கருதிெ ்றெயல்” 
மருத்துவ வழிமுவற: 
✓ தன்னிதல வளரச்ச்ிேதடந்த ஐேத்ததயும், வாதத்ததயும் 
சமப்படுத்த நவண்டும். 
✓ .தன்னிதல வளரச்ச்ிேதடந்த பித்ததத சமப்படுத்த நவண்டும். 









LINE OF TREATMENT: 
  1.Kaapu (prevention) 
  2.Neekam (Treatment) 
  3.Niraivu (Restoration) 
1.Kaapu: 
❖ Prevention is the main aim of siddha system. Siddhars  have described general 
preventive measures and special measures. 
❖ Especially in Balavaagadam, special preventive measures that are said for 
preventive of disease of the child starts from the time of conception in intra 
uterine life and also after delivery. 
❖ The diet of pregnant women, her habits, specific medicine to be taken in each 
month of pregnancy, psychological condition and surroundings influence the 
prevention of disease in the expected child. 
2.Neekam: 
The aim of treatment is as follows: 
❖ To bring the vitiated three dhoshas into normal equilibrium state. 
❖ To treat the patients according to the symptoms by internal medicine – Kana 
nei. 
❖ To Teach them simple breathing exercise which can be followed regularly at 
home. 
3.Niraivu: 
❖ Reassurance of disease recovery was given to all patients. 
❖ All the patients were adviced to have a healthy life style that provides a disease 
free life. 
❖ Anxiety and general fear about the disease was  discouraged by educating the 
patients and their parents. 
❖ All the patients were insisted for regular follow up for the assessment of 
prognosis which regained their confidence about disease recovery. 
 





 “ைத்தியத்தினோநல ைலனுண்டோம் மரு ்து 
  ைத்தியங்கள் நைோல் ைலன் நைோகும்- ைத்தியத்தில் 
  ைத்தியநம றவற்றிதரும் ைண்டிதரக்்கு ஆதலினோல் 
  ைத்தியநம உத்தி றயன்று ைோர்” 
                                                                            -நதவரயர் 
மருந்துண்ணும் காலங்களில் நநாோளியின் நநாயின் தன்தம தபாருத்து 
உணவு மற்றும் தசேல்களில் ஆகும் ஆகா பத்திேங்கள் அறிவுருத்தப்படுகிறது. 
உணவு: 
ஆகும் ைத்தியம்: 
கணம் ந ோயோளிக்கு ஆகும்  கறி விவரம்: 
 “கண்டு றகோள்வோர் கறிவவகக்கு விவரம் நகளு 
  கதலியுட கோயோகும் முருங்வகை் பிஞ்சு 
  கண்டு சிறுகீவர ற ல்லிக்கோய் தோனோகும் 
  தக்க துவவர அவவரயுட பிஞ்சுமோகும் 
  ைண்டு ற ய் ைோல் கற்கண்டு தூதுளங்கோய் ஆகும் 
  ைரிவோன் முயலுடும்பின் இவறெச்ியோகும் 
  றகோண்டுடன் றவள்ளோடு றவள்றளலியும் 
  குலத்திலுள்ள விரோல் மசிறியோகும்” 
                                                                 -மதவலந ோய் றதோகுதி-॥ 
விளக்கம்: 
❖ வாதழக்காே், முருங்தகபிஞ்சு, தநல்லிக்காே், துவதர, அவதரப்பிஞ்சு, 
❖ தூதுங்காே், தநே், பால், கற்கண்டு, முேல் இதறசச்ி, உடும்பு இதறசச்ி,          
❖ தவள்தளலி, விரால்மீன், மசிறி 
❖ இதவ கணம் நநாோளிக்கு ஆகும் உணவு பதாரத்்தமாகும். 
 





❖ குளிரந்்த நீர,் குளிரப்ாணங்கள், ஐஸ்கிரீம், இனிப்பு வதககள்,  
❖ எளிதில் தசரிக்காத மாப்பண்டங்கள். பாகல்,  
❖ அகத்திகீதர, குளிரச்ச்ிோன காே்கறிகள்,  
❖ நநாோளிக்கு ஒவ்வாத பழவதககள். 
ந ோய் தடுை்பு முவற மற்றும் மருத்துவம் அறிவுவர: 
❖ நநாோளி தனக்கு ஒவ்வாத தபாருடக்தள கண்டறிந்து அததன நீக்க 
நவண்டும். 
❖ சுகாரமற்ற உணவுவதககள் மற்றும் நீரிதன தவிரக்்கவும். 
❖ குளிரக்ாற்று, பனிகாற்றில் தவளியில் தசல்வதத தவிரக்்கவும். 
❖ உணவிதன இளஞ்சூட்டில் உண்ண நவண்டும். 
❖ இரவில் உணதவ சீக்கரம் உண்டு சிறிதுநநரம் தசன்ற பின்பு உறங்க 
தசல்ல நவண்டும். 
❖ நநாே் எதிரப்்பு சக்திதே தரும் சத்துள்ள உணவுகதள உண்ண 
நவண்டும். 
❖ புரிந்து தகாள்ளும் வேதிலுள்ள குழந்ததகளுக்கு பிராணாோமம் 
நபான்ற எளிே மூசச்ு பயிற்சி முதறகதள கற்று தருதல் நவண்டும். 
 




       MODERN ASPECT 
 CELLULAR DEVELOPMENT OF LUNG IN UTERO 
 At about 26 weeks of gestation, the lung reaches the stage of full maturity at 
which capable of supporting life the rest of the time spent in the utero from 26 weeks 
to term is for the development and subdivision of the respiratory bronchioles, the 
saccules and for the growth of the airways 
POST- NATAL DEVELOPMENT: 
 At the time of birth there are very few true alveoli, and gaseous exchange take 
place through saccules or terminal airspaces. The alveoli start appearing after birth, first 
on peripheral saccules, then towards proximal respiratory bronchioles and terminal 
bronchioles. About 127 million alveoli are present at one year and about 280 million 
alveoli have developed by age of 8 years. 
PECULARITIES OF RESPIRATORY TRACT IN CHILDREN: 
 Chest wall is thin, elastic yielding and the intrinsic muscles are weak. Short 
thorax with the ribs running more horizontally. Increase in antero-posterior diameter of 
the chest with limited respiration. Epiglottis is longer and projects backwards at a 
greater degree than in older children. 
 All these peculiarities tend to increase the risk of permanent deformity in the 
chest wall in the presence of recurrent or longstanding respiratory distress. By above 8 
years the chest assumes conical shape since the antero-posterior diameter is less than 
the transverse diameter and the ribs are placed in a slightly downward direction. 
 
       ANATOMY & PHYSIOLOGY OF RESPIRATORY SYSTEM 
 Lungs are a pair of Respiratory organs situated in the thoracic cavity. Each lung 
innervates the corresponding pleural cavity. In young, the lungs are brown or grey in 
color. Gradually, they become mottled black because of the deposition of inhaled 
carbon particles. The right lung weights about 700g. It is about 50-100g heavier than 
the left lung. 




      The Respiratory system is a Biological system, consisting of specific organs and 
structures facilitate gas exchange in human. 
 For all air breathing vertebrates, respiration is handled by the lungs, but these 
are far from the only components of the respiratory system. In fact, the system is 
composed of the following biological structures: 
  1.Nose 
  2.Mouth 
  3.Pharynx 
  4.Larynx 
  5.Trachea 
  6.Bronchi and bronchioles 
  7.Lungs 
  8.The muscles of respiration 
 
ANATOMICAL COMPONENTS 
NOSE AND NASAL CAVITY: 
 The nose and the nasal cavity facilitate the main route of air entry. The nose is 
made out of bone, muscle, cartilage and skin, while the nasal cavity is more or less 
hollow space. The nose is typically credited as being the main external breathing 
apparatus. 
 The cavity is lined with mucus membranes and little hairs that can filter the air 
before it goes into the respiratory tract. The two cavities divided by a Septum. 
Anteriorly consist hyaline cartilage. The Roof is formed ethmoid bone. The floor is 
formed by roof of the mouth. The medial wall formed by the septum. The lateral wall 
formed by the maxilla. 
 
 




RESPIRATORY FUNCTION OF THE NOSE: 
 Nose is the entry way to the respiratory tract a passage through the body which 
air uses for travel in order to reach the lungs. The following functions are given below 
            1.Warming: 
                    Due to immense vascularity of the mucosa. 
           2.Filtering and cleaning:  
                    This occurs due to hairs which trap larger particles. 
            3.Humidification: 
                    As air travels over the moist mucosa, it becomes saturated with 
water vapour.    
 ORAL CAVITY: 
  The oral cavity, more commonly referred to as the mouth, is the only other 
external component that is part of the respiratory system. Normally breathing through 
nose is preferable to breathing through the mouth. 
 Not only does the mouth not possess the ability to warm and moisturize the air 
coming in but it also lacks the hairs and mucous membranes to filter out unwanted 
contaminants. On the plus side, the pathway leading from the mouth is shorter and the 
diameter is wider, which means that more ai can entry the body at the same speed. 
PHARYNX: 
 The larynx is the part of the throat that is behind the mouth and nasal cavity and 
above the esophagus and the larynx. Length 12-14cm (extend from the base of the skull 
to the level of 6th cervical vertebra) 
✓ Superiorly consist of Base of the skull 
✓ Inferiorly it continues with the esophagus 
✓ Anteriorly formed by incomplete wall because of the nose, mouth and 
larynx opening. 
✓ Posteriorly – areolar tissues and first 6 vertebra. 




The pharynx is divided into three parts:  
1) Nasopharynx  
2) oropharynx                
3) laryngopharynx  
 The nasopharynx is the upper region of the structure, which begins at the 
posterior of the nasal cavity and simply allows air to travel through it and reach the 
lower sections. 
 The oropharynx does something similar, except it is located at the posterior of 
the oral cavity. Once the air reaches the laryngopharynx, something called the epiglottis 
will divert it to the larynx 
LARYNX: 
 The larynx or voice box extends from the root of the tongue. It lies in front of 
the laryngopharynx at the level of 3rd,4th, 5th and 6th cervical vertebra. Until the puberty 
there is little difference in the size of the larynx between the sexes. The afore mentioned 
epiglottis is part of larynx, as are the thyroid cartilage, the cricoid cartilage and the 
vocal folds. The thyroid cartilage also goes by a more common name – the Adam’s 
apple, although contrary to popular, belief it is present in both men and women. The 
functions of larynx are  
✓ Production of sound 
✓ Speech 
✓ Protection of Lower respiratory tract- during swallowing the larynx 
moves upwards and hinged epiglottis closes over the larynx.  
TRACHEA: 
 Below the larynx is the trachea, or the windpipe. The trachea is the major airway 
for the body and it is made up and held open by hard c- shaped rings of cartilage. The 
cartilage are open at the back (connected by trachealis muscle). The cartilage stiffens 
the trachea and prevents the pipe from collapsing in on itself. This hard cartilage can 
be felt in the front of the neck. The esophagus is behind the trachea. 




 The trachea is lined with mucous membranes. The mucus in the trachea traps 
any foreign particles that get paste the mucus and hairs in the nose. At the bifurcation 
of the trachea, there is the presence of a sensitive carina. Anything that touches the 
carina causes a cough reflex (for protection).  
The function of trachea are  
✓ Support and patency 
✓ Mucociliary escalator 





   The lower end of the trachea splits the respiratory tract into two branches that 
are named the primary bronchi. These first run into each of the lungs before further 
branching off into smaller bronchi. These secondary bronchi continue carrying the air 
to the lobes of the lobes of the lungs, and then further split into tertiary bronchi.   
  The tertiary bronchi then split into even smaller sections that are spread out 
throughout the lungs called bronchioles. Each one of these bronchioles continues to 
split into even smaller parts called terminal bronchioles. The tiny bronchioles do not 
have any kind of cartilage and instead rely on muscles and elastin. The walls of the 
bronchi and bronchioles are also lined with muscle tissue, which can control the flow 
of air going into the lungs. 
LUNGS: 
  The lungs are two organs located inside the thorax on the left and right sides. 
They are surrounded by a membrane that provides them with enough space to expand 
when they fill up with air. The left lung is smaller and has only two lobes while the 
right lung has three.   
Inside the lungs resemble a sponge made of millions of small sacs that are 
named alveoli. These alveoli are found at the ends of terminal bronchioles and are 
surrounded by capillaries through which blood passes.   




PLEURA AND PLEURAL CAVITY:  
The inside of the thoracic cavities and the lung surface are covered with serous 
membranes, respectively the parietal pleura and the visceral pleura, which are in direct 
continuity at the hilum.   
Depending on the subjacent structures, the parietal pleura can be subdivided 
into three portions: the mediastinal, costal and diaphragmatic pleurae. The shape of the 
lungs is determined by the shape of the pleural cavities. Because of the presence of 
pleural recesses, which form a kind of reserve space, the pleural cavity is larger than 
the lung volume.  
The lungs are maintained in close opposition to the thoracic wall by a negative 
pressure between visceral and parietal pleurae. A thin film of extracellular fluid 
between the pleurae enables the lungs to move smoothly along the walls of the cavity 
during breathing.  
MUSCLES OF RESPIRATION: 
  The last component of the respiratory system is a muscle structure known as the 
muscles of respiration. These muscles surround the lungs and allow the inhalation and 
exhalation of air. The main muscle in this system is known as the diaphragm, a thin 
sheet of muscle that constitutes the bottom of the thorax.   
It pulls in air into the lungs by contracting several inches with each breath. In 
addition to the diaphragm, multiple intercostals muscles are located between the ribs 
and they also help compress and expand the lungs.  
BLOOD SUPPLY:  
 The Human Lung has a dual blood supply. 
 The Tissue of the lung receive oxygenated blood via the bronchial circulation, 
a series of arteries that leave the aorta and a part of the systemic circulation. There are 
usually three arteries and they branch alongside the Bronchi and bronchioles. 
 On the right side there is one bronchial artery which arises from either the third 
posterior intercostal artery or from the upper left bronchial artery. On the left side there 
are two bronchial arteries both which arises from descending thoracic aorta. 




 The Blood volume of lungs is about 450 milli meter on average, about 9 percent 
of the total volume of the entire circulatory system.  
 In this process, venous blood in the body collects in the Right atrium and is 
pumped from the right ventricles through the pulmonary trunk and the pulmonary 
arteries into the left and right lungs. 
 The blood passes through small capillaries next to alveoli in the lungs, receives 
oxygen, and travels back to the heart. This is called the pulmonary circulation.  
LYMPHATIC DRAINAGE:  
Superficial vessels drain the peripheral lung tissue lying beneath the pulmonary 
pleura. The vessels pass round the borders of the lung and margins of the fissures to 
reach the hilum. Deep lymphatics drain the bronchial tree, the pulmonary vessels and 
the connective tissue septa. They run towards the hilum where they drain into the 
bronchopulmonary nodes.  
NERVE SUPPLY: 
The lungs are supplied by nerves of the autonomic nervous system. Input from 
the parasympathetic nervous system occur via the vagus nerve. These fibers are               
(i) motor to the bronchial muscles and on stimulation cause bronchospasm. (ii) 
secretomotor to the mucous glands of the bronchial tree and (iii) sensory. The sensory 
fibers are responsible for the cough reflex.  
 When stimulated by acetylcholine, this causes constriction of the smooth 
muscle lining the bronchus and bronchiole, increases the secretion from the glands 
The lungs also have a sympathetic tone from the norepinephrine acting on the 
beta 2 receptors in the respiratory tract, which causes bronchodilation 
The action of breathing takes place because of nerve signal sent by the 









During normal quiet breathing, inspiration is the active process and expiration 
is the passive process. During inspiration, thoracic cage enlarges and lungs expand. 
During expiration, the thoracic cage decrease in size and attain the pre inspiratory 
position. 
MUSCLES OF RESPIRATION:   
The expansion of the chest during inspiration occurs partly voluntary and partly 
involuntary.  The muscles of normal quiet breathing are the intercostal muscles and the 
diaphragm. During difficult breathing they are assisted by the muscles of the neck, 
shoulder and abdomen.   
CYCLES OF RESPIRATION: 
This occurs 12-15 times per minute and consists of three phases.  
1) Inspiration  
2) Expiration  
3) Pause  
INSPIRATION: 
The capacity of the thoracic cavity is increased by simultaneous contraction of 
the inter costal muscles and the diaphragm. The parietal pleura move with the walls of 
thorax and the diaphragm. This reduces the pressure in the pleural cavity to the level 
considerably lower than the atmospheric pressure. The visual pleura follow the parietal 
pleura. During the process, the lungs are stretched; the pressure within the alveoli and 
the air passage reduced drawing air into the lungs in an attempt to equalize the 
atmospheric and alveolar air pressure.  
The process of inspiration is active as it requires expenditure of energy for 
muscle contraction. The negative pressure created in the thoracic cavity aids venous 
return to the heart and is known as respiratory pump.   
 
 





Relaxation of inter costal muscles and the diaphragm results in the downward 
and inward movement of the rib cage and the elastic recoil of the lungs. As this occurs, 
the pressure of the gases inside the thorax exceeds the atmospheric pressure and 
therefore air is expelled from the respiratory tract. The lungs still contain some air and 
are prevented from complete collapse by the intact pleura. The process is passive as it 
does not require the expenditure of energy.  
  After expiration there is a pause, before the next cycle begins.   
Physiology Variables Affects Respiration   
ELASTICITY: 
Loss of elasticity of the connective tissue in the lungs necessitates forced 
expiration and increased effort of inspiration.   
COMPLIANCE:  
The ability of lungs and thorax to expand or the expansibility of lungs and 
thorax is called the compliance. It is defined as the change in volume per unit change 
in the pressure.  
AIR FLOW RESISTANCE:  
When this is increased e.g. in broncho constriction, more respiratory effort is 
required to inflate the lungs.  
 PULMONARY FUNCTION TEST:  
Pulmonary function tests are useful in assessing the functional status of the 
respiratory system both in physiological and pathological conditions. Pulmonary 
function tests are carried out mostly by using spirometer.  
The air in lung is classified into two divisions:  
       I Lung volume  
II Lung capacities 
 





Lung volume:   
 Lung volumes are the volumes of air breathed by an individual during altered 
pattern of respiration. The lung volumes are dynamic and are four types 
 I. Tidal volume  
II. Inspiratory reserve volume  
III. Expiratory reserve volume  
IV. Residual volume  
Tidal Volume (TV): 
  The volume of air breathed in and out of lungs in a single normal quiet 
respiration is called tidal volume. Tidal volume signifies the normal depth of breathing. 
Normal value 500 ml. 
Inspiratory Reserve Volume (IRV): 
An additional amount of air that can be inspired forcefully after the end of 
normal inspiration beyond tidal volume is called the inspiratory reserve volume. 
Normal volume 3300 ml  
Expiratory Reserve Volume (ERV): 
  The additional amount of air that can be expired out forcefully, after normal 
expiration is called the expiratory reserve volume. Normal volume 1000 ml  
Residual Volume:  
Normally, lungs cannot be emptied completely even by forceful expiration. 
Some amount of air always remains in the lungs even after the forced expiration. The 
amount of air remaining in the lungs even after forced expiration is called residual 
volume.  
It is significant because of two reasons:  
I. It helps to aerate the blood in between breathing and during expiration II. It maintains 
the contour of the lungs  




Lung capacities:  
Two or more lung volumes together are called lung capacities. Lung capacities 
are of four types:  
I. Inspiratory capacity  
II. Vital capacity  
III. Functional residual capacity  
IV. Total lung capacity 
Inspiratory capacity (IC):  
  It is the maximum volume of air that is inspired from end expiratory position. 
Inspiratory capacity includes tidal volume and inspiratory reserve volume.   
IC = TV + IRV=500+3300=3800ml  
Vital capacity (VC): 
 It is the maximum amount of air that is expelled out forcefully after a maximal 
(deep) inspiration. Vital capacity includes inspiratory reserve volume, tidal volume and 
expiratory reserve volume.  
VC= IRV+TV+ERV=3300+500+1000=4800ml  
Functional residual capacity (FRV): 
  It is the volume of air remaining in the lungs after normal expiration. Functional 
residual capacity includes expiratory reserve volume and reserve volume.  
                 FRV= ERV+RV=1000=+1200=2200ml  
Total lung capacity (TLC): 
  Total lung capacity is the amount of air present in the lungs after a maximal 
inspiration. It includes all the volumes.  
                        TLC=IRV+TV+ERV+RV=3300+500+1000+1200=6000  
 





This is the volume of air that moves into and out of the alveoli per minute. It is 
the tidal volume minus the anatomical dead space, multiplied by the respiratory rate.  
Alveolar ventilation = (TV-anatomical dead space) respiratory rate = (500-150) ml x 
15 per minute = 5.25liters / minute.  
Lungs function tests are carried out to determine respiratory function and are based on 
the parameters out lined above.   
EXTERNAL RESPIRATION:  
This is the exchange between alveoli and blood. Total area of gas exchange in 
the lungs is 70-80 square meters. CO2 diffuses from venous blood along the contraction 
gradient into the alveoli until equilibrium with alveolar air is reached. By the same 
process O2 diffuses from alveoli to the blood.   
INTERNAL RESPIRATION: 
This is the exchange of air between the tissue and blood. When there is 
difference in partial pressures, oxygen diffuses outward from the blood to extra cellular 
fluid then into the cell walls. The process involved is diffusion.  
CONTROL OF RESPIRATION:  
Control of respiration is normally involuntary. Voluntary control is exerted 
during activities such as speaking, singing but is over ridded if homeostasis of arterial 
PO2 and PCO2 is threatened i.e. if this is high arterial PCO2 or low arterial PO2. 
RESPIRATORY CENTER: 
 The Respiratory centers are divided into three areas on the basics of their 
functions: 
1. The Medullary rhythmicity area in the medulla oblongata 
2. The pneumotaxic area in the pons 
3. The Apneustic area in the pons 
 




The function of Medullary rhythmicity area is to control the basic rhythm of 
respiration.it include two areas. 
 a.Inspiratory Medullary rhythmicity area – When its inspiratory neurons 
fire, a burst of impulse travels along the Phrenic and Intercostal nerves to excite the 
diaphragm and external intercostal muscles. 
 b.Expiratory Medullary rhymicity area – Its causes the contraction of the 
internal intercostal and abdominal muscles, which decreases the size of the thoracic 
cavity and causes forceful exhalation. 
Pneumotaxic Area: 
 It transmits inhibitory impulse to the inspiratory area. The major effect of these 
nerve impulse is to help turn off the inspiratory area before the lungs become too full 
of air. 
Apneustic Area: 
 This area sends stimulatory impulse to the inspiratory area that activate it and 
prolong inhalation. The result is a Long, deep, inhalation. 
 
BRONCHIAL ASTHMA   
DEFINITION: 
 Bronchial asthma is a common chronic inflammatory condition of the airways 
characterized by increased responsiveness of tracheobronchial tree to a variety of 
stimuli resulting in widespread narrowing of the air space. The term “asthma” in Greek 
means “ breathless ” or “ breathe with open mouth ” 
PREVALANCE: 
1. Around 0.5-2 percentage of the population suffers from asthma  
2. 8.9 million children had been diagnosed with asthma in their life time, boys 
(14%) and girls (10%)  




3. The international study on asthma and allergies in childhood (ISAAC) 
reported prevalence of breathing difficulty in 9 % of children in rural area of  Tamil 
nadu.  
4. India has estimated 15 to 20 million asthmatics peoples 
ETIOLOGY: 
 1. Allergens such as Food, Pollens, Dust, Mites and Pet dander. 
 2. Air pollutions and toxins.  
3. Emotional stress and anxiety.  
4. Weather, especially extreme changes in temperature.  
5. Infections bacterial, viral fungal. 
Genetic Predisposition:  
   Genetic factors play a contributing role in the Pathogenesis of asthma. 
Molecular genetic linkage studies indicate that the ‘Atopic’ gene locus is on 
chromosome 11 and the genes for cytokines that are important components in the 
pathogenesis of asthma are encoded in chromosome 5. The allergic cytokines are IL 
3,4,5,9,13 and granulocyte macrophage colony stimulating factor. All these are linked 
to inheritance of an increased Ig E response and increased bronchial responsiveness.  
 
                             





PATHOPHYSIOLOGY OF ASTHMA:  
              Environmental factors + Genetic predisposition 
                                        
                        Bronchial inflammation 
 
        Bronchial hyperactivity + trigger factors 
                                                                              
                    Odema+ Bronchoconstriction +                         UTRI,allergens,smoking,  
                        increase mucous production                        weather,emotional,chemicals                
                                                          
         Airway narrowing 
                                              
  Symptoms manisfestation                               Wheeze,Cold,Chest tightness    
     
            Airway obstruction (or airway narrowing), that is reversible (at least partially), 
either spontaneously or with treatment.  
 Airway inflammation   
 Airway hyper responsiveness to a variety of stimuli  
             Airway obstruction is responsible for the clinical manifestations of asthma such 
as wheezing, dyspnea, and cough.   
  Airway obstruction, which is determined by the diameter of the airway lumen, 
can be influenced by a number of factors, including edema of the bronchial wall, mucus 
production, airway smooth muscle contraction, and airway remodeling suggesting a 
rationale for early initiation of anti- inflammatory therapy.  




                                       
1.Airway inflammation: 
The airways of asthma patients are infiltrated by a number of different 
inflammatory cells, which then cause epithelial disruption and mucosal edema. An 
initial trigger in asthma may cause the release of inflammatory mediators from 
bronchial mast cells, macrophages and epithelial cells.  
 In addition to the release of cytokines by mast cells, T-cells, fibroblasts, 
endothelial cells and epithelial cells activate neutrophils, eosinophils and macrophages, 
which produce chronic allergic inflammation characteristic of asthma.  
           This process produces epithelial injury, abnormalities in neural mechanisms, 
increase in airway smooth muscle responsiveness, and airflow obstruction. Epithelial 
injury can lead to increased permeability and sensitivity to inhaled allergens, irritants, 
and inflammatory mediators.   
 In addition, transduction of fluids and reduced clearance of inflammatory 
substances and respiratory secretions occur with disruption of epithelium mucociliary 
mechanisms. The inflammatory process may chronically irritate the airway leading to 
chronic cough symptoms.  
2.Airway hyperresponsiveness:   
Airway hyperresponsiveness is an exaggerated bronchoconstrictor response to 
many physical, chemical and pharmacological agents e.g., allergens, environmental 
irritants, viral respiratory infections: cold air or exercise.   




  The level of airway hyperresponsiveness usually correlates with the clinical 
severity of asthma and with medication requirement. Atopy, the genetic predisposition 
for the development of an IgE mediated response to common aero allergens, is the 
strongest identifiable predisposing factor for developing asthma.  
   The stimuli that interact with airway responsiveness and incite acute episodes 
of asthma can be grouped into ten major categories – allergic, pharmacological, 
environmental, occupational, infections, and exercise – related and emotional stress, 
food and drink, smoking, heart burn.  
Allergens: 
An allergy with asthma is a common problem. Eighty percent of people with 
asthma have allergies to airborne substances such as tree, grass, and weed pollens, 
mold, animal dander, dust mites, and cockroach particles.  
Allergic asthma is dependent on IgE response controlled by T and B 
lymphocytes and activated by the interaction of antigen with mast cells-bound IgE 
molecule.  
Air pollutants:  
Children with asthma who are exposed to maternal smoking have higher 
requirements for medication and more frequent emergency department visits. Other 
irritants such as wood smoke, household sprays, volatile organic compounds (e.g. 
polishes and cooking oils), and air pollutants may also exacerbate asthma.  
Respiratory infections:  
It is well established that viral respiratory infections can excertable asthma, 
particularly in children with asthma under the age of 10. Respiratory syncytial virus, 
rhinovirus, and influenza virus have been implicated, with rhinovirus being implicated 
in the majority of the exacerbation of asthma in children.   
The role of infections as triggers also appears to be important but not common 
in adults. Respiratory virus may exacerbate asthma through different mechanism. One 
is that viral infections may cause epithelial damage and airway inflammation, both of 
which events may create asthma symptoms.   




In addition, virus has been shown to potentiate the allergic response to allergens by 
increasing the release of inflammatory mediators and the cascade of inflammatory 
events characteristic of asthma.  
 Weather changes: 
 Adverse weather conditions such as freezing temperatures, high humidity, 
thunderstorms and episodes of acute pollution brought out by weather conditions have 
been associated with asthma exacerbations. 
CLASSIFICATION OF ASTHMA: 
Extrinsic asthma (atopic):  
 Nearly 90% of childhood asthma is extrinsic asthma which is allergic asthma.  
It is often associated with a personal and /or family history of allergic diseases such as 
rhinitis, urticaria and eczema. Positive wheal and flare skin reactions to intradermal 
injections of extracts of antigens and increased levels of IgE in serum.  
Intrinsic asthma (non – atopic):  
 A Significant segment of asthmatic population will present with negative 
family or personal history of allergy, negative skin test. They have normal serum levels 
of IgE. Therefore cannot be classified on the basis of defined immunologic 
mechanisms, Many of these will develop a typical symptom complex upon contracting 
an upper respiratory illness, after several days the patient begins to develop paroxysms 
of wheezing and dyspnea that can last for days to months.  
  Asthma – three phenotypes  
 1.Transient Wheezer-onset <3yrs-then resolving  
 2.Persistent wheezer -<3yrs and persisting  








CLINICAL MANIFESTATIONS:  
Cardinal sign:  
The presences of usually diffuse, polyphonic, bilateral and particularly 
expiratory wheeze is the cardinal sign of Asthma.  
Most Common symptoms:   
✓ Intermittent dry cough  
✓ Expiratory wheeze  
✓ Shortness of breath  
✓ Chest tightness  
✓ Intermittent non-focal chest pain  
✓ Nocturnal cough  
✓ Dyspnea  
✓ Limitation of daily physical activity  
✓ General fatigue  
Associated symptoms:  
✓ Allergic rhinitis  
✓ Sneezing  
✓ Itching  
✓ Nasal Congestion  
✓ Gastro esophageal reflux  
 Symptoms of severe persistent asthma:  
 Acute severe attacks on Asthma represent the progression of an attack of 
bronchospasm to the point where the patient is breathless at rest and has the signs of 
cardiac stress. They may be sudden onset, but more commonly build up over several 
hours or days.  
The following are the symptoms of severe persistent asthma:  
✓ Increasing breathlessness  
✓ Difficulty in talking  
✓ Anxiety to the stage of panic  




✓ Feeble Breath sounds  
✓ Absence of Wheeze (Silent chest)  
✓ Profuse sweating, Restless ness  
✓ Fatigue  
✓ Respiratory distress  
✓ Cardiac arrhythmias  
✓ Pulsus paradoxus  
✓ Cyanosis  
✓ Visible overinflated chest (Barrel shaped)  
✓ Difficulty in feeding  
✓ Inability to talk in words or sentences  
DIAGNOSIS: 
  The diagnosis of asthma is a clinical one. Hence detailed  clinical  history taking, 
physical examination and additional information  regarding family history of Atopy, 
allergic exposures, circadian variations and seasonal exacerbations should be carefully 
considered. 
DIFFERENTIAL DIAGNOSIS:  
✓ Bronchiolitis  
✓ Aspiration of foreign body  
✓ Hypersensitivity pneumonitis  
 




   TRIAL DRUG REVIEW 
PREPARATION AND PROPERITIES OF TRIAL DRUGS 
KANA NEI (INTERNAL MEDICINE) 
1.பருத்திவிதத பருப்பு: 
 BOTANICAL NAME: Gossipium herbacium 
 ENGLISH NAME: Cotton plant 
 FAMILY NAME: Malvaceae 
 SUVAI: Thuvarpu, Inipu 
 THANMAI: Veppam 
 PIRIVU: Kaarpu 
பபொது குணம்: 
“பருத்தியிதை பமொக்கிரண்தைப் பொலிைதரத் துண்ண 
 வருத்துகின்ற மமகபமை்ைொம் மொறும் – பருத்த 
 விரத்தபித்தத் மதொடு விரணவீக் கம்மபொம் 
 அரத்தவிதழ் மொமத யதற” 
 
ACTIONS: 
 Expectorant, laxative 
CHEMICAL CONSTITUENTS: 
 Flavonoids, Tannins, Saponin, terpenoids 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Expectorant, Antibacterial, Astringent 
 





BOTANICAL NAME: Phyla nodifera 
 ENGLISH NAME: Purple lippia 
 FAMILY NAME: Verbenaceae 
 SUVAI: Kaipu, Thuvarpu 
 THANMAI: Veppam 
 PIRIVU: Kaarpu 
பபொது குணம்: 
“பபொடுததையின் மபருதரத்தொை் மபொரொமப் மபொக்கும் 
 அடுததைபெய் கொெம் அைங்கும் – கடுகிவரு 
 மபதிபயொடு சூதைம ொய் மபெரிய பவண்மமகம் 
 வொதமும்மபொ பமய்யுரக்கும் வொழ்த்து” 
ACTIONS: 
 Expectorant, Demulcent, astringent 
CHEMICAL CONSTITUENTS: 
 Nodifloridin A, Nodifloridin B, Lippiflorin A, Lippiflorin B 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Expectorant, Anti spasmodic, Astringent 
 
3.கிரொம்பு: 
 BOTANICAL NAME: Syzygium aromaticum 
 ENGLISH NAME: Clove 
 FAMILY NAME:  Myrtaceae 









“பித்த  மயக்கம் மபதிபயொடு வொ ்தியும்மபொம் 
  சுத்தவிரத் தக்கடுப்பு ் மதொன்றுமமொ- பமத்த 
  இைவங்கங் பகொமண்ைவருக் மகற் சுகமொகும் 
  மைமங்மக கை்டுபமன வொழ்த்து.  
 
  சுக்கிை ை் ைங்கரண் சூரவ்ியங்க ைொகஞ்ென ்தொை் 
  சிக்கை்விைொெ ்ெரவ்ொ சியப்பிணியு- மக்கிக்குை் 
  ைங்கப் பூமவொடு தரிபைரு ் மதொன்றிலிை் 
  வங்கப்பூ மவொடுதர ்து வொ” 
 
ACTIONS: 
 Anti-spasmodic, Carminative, Stomachic 
CHEMICAL CONSTITUENTS: 




 Anti-inflammatory, Carminative, Anti spasmodic, Anodyne 
 





 BOTANICAL NAME: Curcuma zedoaria 
 ENGLISH NAME: Round white zedoary 
 FAMILY NAME: Zingiberaceae 
 SUVAI: Kaipu 
 THANMAI: Veppam 
 PIRIVU: Kaarpu 
“ ற் கிெச்ிலியி பணொண்கிழங் குங்கபமும் 
    பூை்டுமுை மும்புண்ணும் மபொம்” 
ACTIONS: 
 Expectorant, Stimulant, Alterative, Carminative 
CHEMICAL CONSTITUTIONS: 
 Borneol, Furanodiene, Furanodienone, camphene 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Expectorant, Carminative Anti allergic 
 
5.சீரகம்: 
 BOTANICAL NAME: Cuminum cyminum 
 ENGLISH NAME: Cumin seeds 
 FAMILY NAME: Umbellifers 
 SUVAI: Kaarpu, Inippu 
 THANMAI: Thatpam 
PIRIVU: Inippu 





“பித்தபமனு ம ்திரிதயப் பின்ன படுத்தியவன் 
 ெத்துருதவ யு ்துற ்து ெொதித்து- மத்தபனனும் 
 ரொெதனயு மீபவன்று ண்தபப் பைப்படுத்தி 
 மபொெனகு ைொரிபெயும் மபொர்” 
 
ACTIONS: 
 Carminative, Stimulant, Astringent 
CHEMICAL CONSTITUTIONS: 
 Cuminosides A & B, Cumin aldehyde, Luteolin, Estrogole, Camphene 
PHARMACOLOGICAL AVTIVITIES: 
 Anti-inflammatory, Bronchodilator, Antimicrobial 
 
6.இைவம் பிசின்: 
 BOTANICAL NAME: Bombax malabaricum 
ENGLISH NAME: capok tree or cotton tree 
 FAMILY NAME: Bombacaceae 
 SUVAI: Inipu, Thuvarppu 
 THANAMI: Thatpam 









“த ்துமம கஞ்சிறு ீரத்் தொதரபவப் பம்வொயு 
 வு ்தவரு மபதியிதவ மயொை்டுங்கொண் – மு ்திக் 
 கிளரவ்ள்தள பொயும்வரிக் பகொண்தை விழியொய் 
 வளரம்ுள் ளிைவு மரம்” 
 
ACTIONS: 
 Astringent, styptic 
CHEMICAL CONSTITUTIONS: 
 Kaempferol, Anthocyanin A, Anthocyanin B. 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Astringent, Anti pyretic, Antimicrobial 
 
7.இைவங்கப்பைத்ை: 
 BOTANICAL NAME: Cinnamomum verum 
 ENGLISH NAME: Bark of cinnamon 
 FAMILY NAME: Lauraceae 
 SUVAI: Kaarpu, Inippu 
 THANMAI: Thatpam 









“தொது ை்ைம் மபதி ெருவவிஷம் ஆகியம ொய் 
 பூதகிர கஞ்சிை ்திப் பூெச்ிவிைஞ்- ெொதிவிைம் 
 ஆை்டுமிதரப் மபொடிருமை் ஆகியம ொய்க் கூை்ைமற 
 ஓை்டுமிை வங்கத் துரி” 
ACTIONS: 
 Carminative, Stimulant 
CHEMICAL CONSTITUTIONS: 
 Cinnamyl acetate, Eugenol, Cinnamaldehyde, Coumarin 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Carminative, Stimulant, Antimicrobial 
 
8.ெொதிக்கொய்: 
 BOTANICAL NAME: Myristica fragrans 
 ENGLISH NAME: Nut meg 
 FAMILY NAME: Myristicaceae 
 SUVAI: Thuvarpu, Kaarpu 
 THANMAI: Veppam 










“தொது ை்ைம் மபதி ெருவொசி யஞ்சிர ம ொய் 
 ஓதுசுவொ ெங்கொெம் உை்கிரணி- மவமதொ 
 டிைக்கொய் வரும்பிணிமபொம் ஏற்றமயை் பித்தங் 
 குைக்கொ யரு ்துவரக்்குக் கூறு” 
ACTIONS: 
 Stimulant, Carminative, Tonic 
CHEMICAL CONSTITUTUIONS: 
 Eugenol, Isoeugenol, Methyl eugenol, Myristicin, Elemicin, Trimyristin. 
PHARMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Carminative, Antibacterial, Astringent 
9. கொய்ெச்ுக்கை்டி: 
 BOTANICAL NAME: Catechu lozenges 
 FAMILY NAME: Fabaceae 
 SUVAI: Thuvarppu 
 THANMAI: Thatpam 
 PIRIVU: Inippu 
ACTIONS: 
  Styptic, carminative 
CHEMICAL CONSTITUTIONS: 
 Catechin, Quercetin, Vanillic acid, Ferulic acid 
PHARAMACOLOGICAL ACTIVITIES: 
 Anti-inflammatory, Antibacterial, Astringent, Antioxidant 





10. பசு ப ய் : 
SUVAI: Inippu 
 THANMAI: Thatpam 
 PIRIVU: Inippu 
 
பபொது குணம்: 
 “தொகமுழ தைசுை்கம் வொ ்தி பித்தம் வொயுபிர 
   மமகம் வயிற்பறரிவு விக்கைழை் – மொகொெங் 
   குன்மம் வறை்சி குைற்புரை்ை ைஸ்திசுை்கஞ் 
   பெொன்மூைம் மபொக்கு ிதறத் துப்பு.” 
 
ACTIONS ON THE DOSHAS: 
 Tridoshaic – balance Vatha, Pitha Kapha 
ACTIONS: 
 Anti-fungal, Anti-oxidant, Anti-aging, Anti-bacterial, Anti-viral 
CHEMICAL CONSTITUENTS: 
 Cow Ghee’s is abadunt in saturate fatty acids. It contains Approximately 8% 
saturated fatty acid which make it easily digestible. The digestible co- efficient or the 
rate absorption is 96% which is better than any other animal or vegetable fat. 
 It contains Triglyceride, diglycerides, monoglyceride, phospholipids contain 









✓ It is cooling, tasty, tonic, appetizer 
✓ It increases our capacity to digest food but also our capacity to absorb 
and assimilate it. 
✓ It Increase intelligence, refines the intellect and improve the memory. 
✓ It directly nourishes our immune system, as well as our life force and all 
of our tissues. 
✓ It can stimulate secretion of stomach acid and thus helping in the 
digestive process. 
✓ It increases the absorbability of Vitamin and minerals and thus help to 
improve overall health. 
✓ It Balances all Agni (Digestive fires) 
✓ Ghee increase the strength, luster and beauty of the body. 
 
 
STANDARD OPERATING PROCEDURES OF KANA NEI: 
SOURCE OF TRIAL MEDICINE: 
 The raw drug for the preparation of Kana nei will be purchased from a well 
reputed country shop and the purchased drugs will be authenticated by the competent 
authority (Medicinal Botany dept, GSMC, Chennai). After that the raw drugs will be 
purified separately then the trial drugs will be prepared in Gunapadam Laboratory of 
Government Siddha Medical college, Chennai-106 
 
RAW DRUGS IDENTIFICATION AND AUTHENTICATION: 
 These ingredients were identified and were authenticated by Medicinal Botanist 
at GSMC, Arumbakkam, Chennai-600106.  
 
 




INGREDIENTS OF KANA NEI: 
1. PARUTHIVITHAI PARUPPU (Gossipium herbacium)    - 21gm 
2. PODUTHALAI KAAI (Phyla nodifera)                             - 21gm 
3. KIRAMBU (Syzygium aromaticum)                                    - 21gm 
4. KICHILI KIZHANGU (Curcuma zedoaria)                       - 21gm 
5. SEERAGAM (Cuminum cyminum)                                     - 21gm 
6. ELAVAMPISIN (Bombax malabaricum)                            - 21gm 
7. ELAVANGAPATTAI (Cinnamomum verum)                     - 21gm 
8. JAATHI KAAI (Myristica fragrans)                                    - 21gm 
9. KAAICHUKATTI (Catechu lozenges)                                -  21gm 
10. COW GHEE                                                                          - 350 ml 
METHODS OF PURIFICATION: 
 Raw drugs are purified a mentioned in sikicharatna deepam sarakku suthi 
muraigal. 
PARUTHIVITHAI PARUPPU: 
 Dried in sun shade and fried 
PODUTHALAI KAAI: 
 Dried in sun shade  
KIRAMBU: 




 Dried in sun shade and fried 
ELAVAM PISIN: 
 Dried in sun shade and powdered 





 Dried in sun shade and fried 
JAATHIKAAI: 
 Remove the outer cover, cut into small pieces and dried in sun shade 
KAAICHUKATTI: 
 Dried in sun shade and powdered 
COW GHEE: 
 melt and then used. 
PREPARATION OF DRUG: 
 The above mentioned 9 raw drugs are purified and mildly fried separately made 
it into fine powder. Then the fine powder is mixed into ghee and the mixture is heated 
upto 2-3 boils and mixed well. 
DOSE: 
  3 to 5 years - 1gm Twice a day 
  6 to 12 years - 2gm Twice a day 
DURATION: 
 21 Days 
REFERENCE: 
 Anuboga vaithiya kunabodhini 
  Kuzhanthaigal Avushatham 
          Dr. Vasudevan 
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PRECLINICAL SAFETY STUDIES FOR  KANA NEI 
• Biochemical analysis 
• Phytochemical analysis 
• Physicochemical analysis 
• TLC analysis & HPTLC analysis 
• Specific pathogen 
• Sterility test 
• Heavy metal analysis 
• Analysis of pesticides organochlorine, organophosphorus and 
pyrethroida 
• Aflotoxins 
• Aute Toxicity study 
• Repeated oral toxicity study 28 days 
• Pharmacological Activity 


















III. Bio Chemical analysis of trial medicine Kana Nei for Soolikanam 
(Childhood bronchial asthma)  
Preparation of sodium carbonate extract  
  2 gm of Kana nei sample is mixed with 5gm of sodium carbonate and 
taken in a 100 ml beaker and 20 ml of distilled water is added. The solution is boiled for 
10 minutes,cooled and then filtered. The filtrate is called sodium carbonate extract.  
S.NO EXPERIMENT OBSERVATION INFERENCE 
Test for Acid Radicals 
1A Test for sulphate: 2ml of the 
above prepared extract is taken 
in a test tube.to this add 2ml of 4 
% Ammonium oxalate solution. 
Absence of white 
precipitate 
Absent 
B 2ml of extract is added with 2ml 
of dilute Hydrochloric acid until 
the effervescence ceases 
off.Then 2ml Barium chloride 
solution is added. 
Absence of white 
precipitate 
Absent 
2 Test for chloride: 2ml of extract 
is added with dilute Nitric acid 
till the effervescence 
ceases.Then 2ml of silver nitrate 
solution is added. 










3 Test for phosphate: 2 ml of the 
extract is treated with 2 ml of 
Ammonium molybdate solution 
and 2 ml of concentrated nitric 
acid 
Absence of  Yellow 
precipitate 
Absent 
4 Test for carbonate: 2 ml of the 
extract is treated with 2 ml of 
Magnesium sulphate solution. 
Absence of white 
precipitate 
Absent 
5 Test for sulphide: 1 gm of the 
substance is treated with 2 ml of 
concentrated Hydrochloric acid. 
Absence of  Rotten 
egg smelling 
Absent 
6 Test for Fluoride and oxalate: 
2ml of extract is added with 
dilute Acetic acid and 2 ml of 
Calcium chloride solution and 
heated. 
Absence of white 
precipitate 
Absent 
7 Test for Borate: 2 pinches of 
the substance is made into paste 
by using Sulphuric acid and 
alcohol (95%) and introduced 
into the blue flame. 
Absence of Green 
tinged flame 
Absent 
   
TEST FOR BASIC RADICALS 
8 Test for lead:  
2 ml of the extract is added with 
2 ml of Potassium iodide  
solution.  












9 Test for copper:  
One pinch of substance is made 
into paste with concentrated 
Hydrochloric acid in a watch 
glass and introduced into the 
nonluminous part of the flame. 
Absence of  Bluish 
green colored flame 
Absent 
10 Test for aluminium: 
 To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of white 
precipitate 
Absent 
11 Test for iron:  
To the 2 ml of extract 2ml of 
Ammonium thiocyanate solution 
and 2ml of concentrated Nitric 
acid is added. 
 





12 Test for zinc:  
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of green 
tinged flame 
Absent 
13 Test for calcium:  
To the 2 ml of extract 
Ammonium oxalate solution 














14 Test for magnesium: 
 To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess 




15 Test for ammonium:  
To the 2 ml of extract few ml of 
Nessler‟s reagent and excess of 
Sodium hydroxide solution are 
added 
Absence of white 
precipitate 
Absent 
16 Test for sodium:  
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and introduced 
into the blue flame 





17 Test for mercury:  
2 ml of extract is treated with 2ml 
of Sodium hydroxide solution. 
Absence of Yellow 
precipitate 
Absent 
18 Test for arsenic: 
 2 ml of extract is treated with 
2ml of Silver nitrate solution. 
Absence of white 
precipitate 
Absent 
19 Test for starch:  
2 ml of extracts treated with weak 
iodine solution. 
Presence of white 
precipitate 
Present 
20 Test for reducing sugar  
5ml of Benedicts qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 












added 10 drops of the extract and 
again boiled for 2minutes.The 
colour changes are noted.  
 
21 Test for alkaloids:  
2 ml of the extract is treated with 
2ml of Potassium iodide solution. 









 Iron, Calcium, Starch, Reducing sugar. 
  
     PHYTOCHEMICAL ANALYSIS 
 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
 
Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 









Test for saponins:  
To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
 To the test sample, ferric chloride was added, formation of a dark blue or greenish 
black color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water 
bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered 
hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is separated and 
10% ammomia solution is added to it. Pink colour indicates presence of glycosides. 
Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added followed 
by addition of few drops of conc. Sulfuric acid. Appearance of yellow color indicates the 
presence of Flavonoids. 
 
Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was added. A 
bulky white precipitate indicated the presence of phenolic compounds. 
 
Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. Sulphuric 
acid (3ml), and shaken well. The upper layer in the test tube was turns into red and 











Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
 
Test for Cyanins 
A. Aanthocyanin: 
        To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min 
at 100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is heated 
on a boiling water bath for 2 minutes. A characteristic coloured precipitate indicates the 
presence of sugar. 
 
Proteins (Biuret Test) 
To extracts 1% solution of copper sulphate was added followed by 5% solution of 




















                                
 
                 
    
                                        
 
Test for Alkaloids, Flavonoids, Glycosides, Steroids ,Triterpenoids  











Phytochemical Analytical Report 
 
 
S.NO TEST OBSERVATION 
1 ALKALOIDS  
2 FLAVANOIS + 
3          GLYCOSIDES + 
4 STEROIDS + 
5    TRITERPENOIDS + 
6 COUMARIN + 
7 PHENOL + 
8 TANIN - 
9 PROTEIN - 
10 SAPONINS - 
11 SUGAR + 
12 ANTHOCNIN - 
13           BETACYANIN + 
+ -> Indicates Positive and - -> Indicates Negative 
 
 
 PHYSICOCHEMICAL ANALYSIS 
 Sample Description                                                        Solubility profile  of KAN 










State Semi solid 
Appearance Pale Brownish 
Odour Characteristic odor 
Nature Greasy 
 
S.No Solvent Used Solubility / Dispersibility 
1 Chloroform Soluble 
2 Ethanol Insoluble 
3 Water Insoluble 
4 Ethyl acetate Soluble 
5 Hexane Soluble 
6 DMSO Insoluble 
 
Determination of Iodine value  
About 20 gm of test sample was transferred into Iodine flask. To which 10 ml of 
chloroform was added and warmed slightly and cooled for 10 minutes. Followed by this 
about 25 ml of Wiji’s solution was added in the same flask and shaken well. The flask was 
allowed to stand for 30 mins and refrigerated for an hour. About 10 ml of KI solution was 
added to this and titrated against 0.1 N Sodium thiosulphate solutions until the appearance 
of yellow colour. 1 ml of starch indicator was added and again titrated against the sodium 








Repeat the above procedure without taking sample and note the corresponding reading for 
blank titration. 
 
Determination of saponification value  
About 2 gm of test sample was transferred into the round bottomed flask. To this 
about 20 ml of 0.5 N alcoholic KOH solutions was added to the round bottomed flask. 
Repeat the same procedure with out taking the sample for blank titration . Reflux both 
sample and blank round bottomed flasks for 1 hour. After reflux, allow both the round 
bottomed flasks to cool. Titrate the samples using 0.5 N HCl with phenolphthalein 
indicator. The disappearance of pink indicates the end point.  
 
Determination of Viscosity value  
Viscosity determination were been carried out using Ostwald viscometers. 
Measurement of viscosity involves the determination of the time required for a given 
volume of liquid to flow through a capillary. The liquid is added to the viscometer, pulled 
into the upper reservoir by suction, and then allowed to drain by gravity back into the lower 
reservoir. The time that it takes for the liquid to pass between two etched marks, one above 
and one bellow the upper reservoir, is measured. 
 
Determination of Refractive Index 
Determination of RL was carried out using Refractometer. 
 
Determination of Weight per ml 
   Weight per ml was determined using the comparative weight calibration method, 
in which the weight of 1ml of the base of the formulation was calculated and then weight 
of 1 ml of finished formulation were been calculated. The difference between weight 











Accurately 5 g of test sample was weighed and transferred into a 250 mL conical 
flask. To this, a 50 mL of neutralized alcohol solution was added. This mixture was heated 
for 10 min by heating mantle. Afterwards, the solution was taken out after 10 min and 1 or 
2 drops of phenolphthalein indicator was added. This solution was titrated against KOH 
solution from the burette. The appearance of pink color indicated the end point. The volume 
of consumed KOH solution was determined and the titration of test sample was carried out 
in triplicate and the mean of the successive readings was used to calculate the acid-value 
of the respective sample by following expression. 
Acid value = Titter Value X 0.00561X 1000 / Wt of test sample (g) 
 
Peroxide value 
5 g of the substance being examined, accurately weighed, into a 250-ml glass-
stoppered conical flask, add 30 ml of a mixture of 3 volumes of glacial acetic acid and 2 
volumes of chloroform, swirl until dissolved and add 0.5ml volumes of saturated potassium 
iodide soluton. Allow to stand for exactly 1 minute, with occasional shaking, add 30 ml of 
water and titrate gradually, with continuous and vigorous shaking, with 0.01M sodium 
thiosulphate until the yellow colour almost disappears. Add 0.5 ml of starch solution and 
continue the titration, shaking vigorously until the blue colour just disappears (a ml). 
Repeat the operation omitting the substance being examined (b ml). The volume of 0.01M 




S.No Parameter KAN 








2 Refractive index  1.44 
3 Weight per ml (gm/ml) 
0.073 
gm/ml 
4 Iodoine value (mg I2/g) 97.155 
5 
Saponification Value                                                                  
(mg of KOH to saponify 1gm of fat) 194.56 
6 Acid Value mg KOH/g 0.5049 
7 Peroxidase Value mEq/kg 4.063 
 
 TLC AND HPTLC ANALYSIS OF KANA NEI 
TLC Analysis 
Test sample was subjected to thin layer chromatography (TLC) as per conventional one 
dimensional ascending method using silica gel 60F254, 7X6 cm (Merck) were cut with 
ordinary household scissors. Plate markings were made with soft pencil. Micro pipette 
were used to spot the sample for TLC applied sample volume 10-micro liter by using 
pipette at distance of 1 cm at 5 tracks. In the twin trough chamber with the specified solvent 
system After the run plates are dried and was observed using visible light Short-wave UV 
light 254nm and light long-wave UV light 365 nm 
 
High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to achieve 
precision, sensitive, significant separation both qualitatively and quantitatively. High 
performance thin layer chromatography (HPTLC) is a valuable quality assessment tool for 
the evaluation of botanical materials efficiently and cost effectively. HPTLC method offers 
high degree of selectivity, sensitivity and rapidity combined with single-step sample 
preparation. In addition it is a reliable method for the quantitation of nano grams level of 








It provides chromatographic fingerprint of phytochemicals which is suitable for confirming 
the identity and purity of medicinal plant raw materials.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried 
out according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried. 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values were 
tabulated. 
 
               
            
          TLC ANALYSIS                              HPTLC finger printing                                                                    
                                                                                 Of sample K                                                                                          
                         
 
 




      
 SPECIFIC PATHOGEN TEST FOR KANA NEI 
Test for Specific Pathogen 
Methodology 
Test sample was directly inoculated in to the specific pathogen medium (EMB, 
DCC, Mannitol, Cetrimide) by pour plate method. The plates were incubated at 37oC 
for 24 - 72h for observation. Presence of specific pathogen identified by their 
characteristic color with respect to pattern of colony formation in each differential 
media. 
 
Detail of Specific Medium and their abbreviation 
Organism Abbreviation Medium  
E-coli EC EMB Agar 
Salmonella SA Deoxycholate agar 
Staphylococcus Aureus ST Mannitol salt agar 
Pseudomonas 
Aeruginosa 
PS Cetrimide Agar 
 
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculated with the 
test sample. 
 
Organism Specification Result Method 
E-coli Absent Absent  
As per AYUSH 
specification 
Salmonella Absent Absent 












Culture plate with Pseudomonas Aeruginosa (PS) specific medium 
                                
Culture plate with Salmonella (SA) specific medium 
                                
Culture plate with Staphylococcus Aureus (ST) specific medium 
                                 
 Culture plate with Pseudomonas Aeruginosa (PS) specific medium 
                                 
 
 





      STERILITY TEST FOR KANA NEI 
STERILITY TEST BY POUR PLATE METHOD 
Objective  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of 
colonies. The colonies are referred to as Colony Forming Units (CFUs).   
Methodology 
Test sample was admixed with sterile distilled water and the mixture were been used 
for the sterility evaluation. About 1ml of the test sample was inoculated in sterile petri 
dish to which about 15 mL of molten agar 45oC were added. Agar and sample were 
mixed thoroughly by tilting and swirling the dish. Agar was allowed to completely gel 
without disturbing it. (about 10 minutes). Plates were then inverted and incubated at 
37o C for 24-48 hours. Grown colonies of organism was then counted and calculated 
for CFU.  
                                      
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculates with the 
test sample. 
Test Result Specification As per 
AYUSH/WHO 
Total Bacterial Count Absent NMT 105CFU/g As per AYUSH 
specification 
Total Fungal Count Absent NMT 103CFU/g 
 
 





HEAVY METAL ANALYSIS BT AAS 
 




Atomic Absorption Spectrometry (AAS) is a very common and reliable technique 
for detecting metals and metalloids in environmental samples. The total heavy 
metal content of the sample was performed by Atomic Absorption Spectrometry 
(AAS) Model AA 240 Series. In order to determination the heavy metals such as 




Test sample was digested with 1mol/L HCl for determination of arsenic 
and mercury. Similarly for the determination of lead and cadmium the sample 
were digested with 1mol/L of HNO3. 
 
Standard reparation 
   
  As & Hg- 100 ppm sample in 1mol/L HCl 
                        Cd & pb – 100 ppm sample in mol/L HNO3 
                                                 
 









Mercury 253.7 nm BDL 1 ppm 
Lead 217.0 nm BDL 10 ppm 
Arsenic 193.7 nm BDL 3 ppm 
Cadmium 228.8 nm BDL 0.3 ppm 
 
BDL   - Below Detection limit 
 
Report and inference 
 
• Results of the present investigation have clearly shows that the sample has no 










ANALYSIS OF PESTICIDE ORGANOCHLORINE, ORGANOPHOSPHORUS AND 
PYRETHROIDS  
Extraction 
 Test sample were extracted with 100 ml of acetone and followed by 
homogenization for brief period. Further filtration was allowed and subsequent addition of 
acetone to the test mixture. Heating of test sample was performed using a rotary evaporator at a 
temperature not exceeding 40ºC until the solvent has almost completely evaporated. To the 
residue add a few milliliters of toluene R and heat again until the acetone is completely 
removed. Resultant residue will be dissolved using toluene and filtered through membrane 
filter. 
Test Result Analysis of the Sample 
KAN 
 
Pesticide Residue  
Sample KAN 
 
AYUSH Limit (mg/kg) I .Organo Chlorine Pesticides 
Alpha BHC BQL 0.1mg/k
g 
Beta BHC BQL 0.1mg/k
g 
Gamma BHC BQL 0.1mg/k
g 
Delta BHC BQL 0.1mg/k
g 
DDT BQL 1mg/kg 
Endosulphan BQL 3mg/kg 
II.Organo Phosphorus Pesticides   
Malathion BQL 1mg/kg 
Chlorpyriphos BQL 0.2 mg/kg 
Dichlorovos BQL 1mg/kg 
III.Pyrethroid   
Cypermethrin BQL 1mg/kg 
BQL- Below quantification Limit 
Result: The results showed that there were no traces of pesticides residues such as Organo 
chlorine, Organo phosphorus and pyrethroids in the sample provided for analysis. 
 
 





AFLATOXIN STUDY FOR KANA NEI 
Standard 





 Standard samples was dissolved in a mixture of chloroform and acetonitrile 
(9.8:0.2) to obtain a solution having concentration of 0.5 µg per  ml each of aflatoxin B1 
and aflatoxin G1 and 0.1 µg per ml each of aflatoxin B2 and aflatoxin G2 
TEST SOLUTION:  Concentration 1 µg per ml 
PROCEDURE 
 Standard aflatoxins was applied on to the surface to pre coated TLC plate in the volume 
of 2.5 µL, 5 µL,7.5 µL and 10 µL.Similarly the test sample was placed and Allow the spots to 
dry and develop the chromatogram in an unsaturated chamber containing a solvent system 
consisting of a mixture of chloroform, acetone and isopropyl alcohol (85:10:5) until the solvent 
front has moved not less than 15cm from the origin. Remove the plate from the developing 
chamber, mark the solvent from and allow the plate tp air- dry. Locate the spots on the plate by 
examination under UV light at 365nm. 
 
 RESULT: 
 The results shown that there was no spots were been identified in the test sample 
loaded on TLC plates when compare to the standard, which indicates that the sample 
were free from aflatoxin B1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2. 
Aflatoxin Sample KAN AYUSH Specification 
Limit 
B1 Not Detected - Absent 0.5 ppm 
B2 Not Detected - Absent 0.1 ppm 
G1 Not Detected - Absent 0.5 ppm 
G2 Not Detected - Absent 0.1 ppm 
 
 





   ACUTE ORAL TOXICITY STUDY OF KANA NEI (OECD GUIDELINE-423) 
Introduction: 
❖ The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
❖ Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgement on the acute toxicity of 
the test substance.  
❖ This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
❖ The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification 
purposes and hazard assessment.  
❖ In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
❖ The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
❖ The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. 
Absence or presence of compound-related mortality of the animals dosed at one step 
 
 




will determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and the 
weight (150-200gm) should fall in an interval within±20 % of the mean weight of any 
previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals may 
be group-caged by dose, but the number of animals per cage must not interfere with 
clear observations of each animal. 
Preparation of animals:  
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, Chennai. All the animals were kept under standard 
 
 




environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Sai meera foods, Bangalore). 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration 
of the,KANA NEI.  
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
 
IAEC Approved Number: LV/10/CLBMCP/2018 
 
Test Substance  : KANA NEI 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
                                marking by using Picric acid.  
Number of animals               : 3 Female/group,  
 Route of administration      :   Oral  
 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, 
Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
 
 




Housing & Environment : The animals were housed in Polypropylene cages  
                   provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
  
Administration of Doses:  
 KANA NEI was suspended in water and administered to the groups of wistar 
albino rats in a single oral dose by gavage using a feeding needle. The control group 
received an equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. 
Following the period of fasting, the animals were weighed and then the test substance 
was administered. Three Female animals are used for each group. The dose level of 5, 
50, 300 and 2000 mg/kg body weight was administered stepwise. After the substance 
has been administered, food was withheld for a further 3-4 hours. The principle of 
laboratory animal care was followed. Observations were made and recorded 
systematically and continuously as per the guideline after substance administration. The 
visual observations included skin changes, mobility, aggressively, sensitivity to sound 
and pain, as well as respiratory movements. Finally, the number of survivors was noted 
after 24 hrs and these animals were then monitered for a further 14 days and 




Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
 
 




which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
 
Acute oral toxicity study of KANA NEI 
Table 1: Dose finding experiment and its behavioral Signs of acute oral 
Toxicity 
Observation done: 
SL              Group 
              CONTROL 
Observation SL Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of posture Normal 2 Assessments of posture Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
 
 




6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant color 
change 
7 Change in skin color No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 
10 Sensitivity response Normal 10 Sensitivity response Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle gripness Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours which  
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, 
convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, loss of 
traction, piloerection  reactivity of touch, salivation, scratching, sedation, chewing,  
head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, sleep and 
coma.  
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
Food and water Consumption: 









           Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test ,description of toxic symptoms,, 
weight changes, food and water intake 
No of animals in each group:3 





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 




+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhea 18. Writhing  
19. Respiration 20. Mortality. 
(+  Present, -  Absent) 









1 7 14 
CONTROL 240.2±12.30  261.4 ± 14.12 276.6 ±16.18 
HIGH DOSE 224.4± 14.22 228 ± 3.14 232.4 ± 2.22 
P value (p)* NS NS NS 
 
 











1 6 14 
CONTROL 81 ± 2.12 84±2.32 88.8±1.24 
HIGH DOSE 72.2±1.1 74.2±1.24       78.20±33 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 





1 7 14 
CONTROL 96.24±1.32 96.2±1.46 98.4±3.26 
High DOSE 78.2±1.42 74.6±2.32 72.1±2.28 
 
  REPEATED DOSE 28-DAYS ORAL TOXICITY (407) 
                       STUDY OF KANA NEI 
 
Test Substance  : KANA NEI 
Animal Source  : TANUVAS, Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
 
 




Identification of animals : By cage number, animal number   and    individual  
   marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai Meera Foods Pvt Ltd,    
                               Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
                   provided with bedding of husk. 
Housing temperature :  between 22ºC±3ºC.    
Relative humidity  :  between 30% and 70%,Air changes   
 : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 6 
 KN - KANA NEI 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for  28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
Groups No of Rats 
Group I Vehicle control (Water) 12(6male,6 female) 
Group II  KN - low dose X (30mg) 12 (6male,6 female) 
Group III  KN - Mid dose 5X (150mg) 12 (6male,6female) 
Group IV  KN - High dose 10X(300mg) 12(6male,6female) 
 
 




Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose (5X), high dose (10X). X is calculated by multiplying the acute 
toxicity dose 2000mg) and the body surface area of the rat (0.018). i.e X dose is 
(30mg/kg), 5X dose is (150mg/kg), 10X dose is (300mg/kg). 
 
Preparation and Administration of Dose: 
        KANA NEI suspended in with water, It was administered to animals at the dose 
levels of X, 5X, 10X. The test substance suspensions were freshly prepared every two 
days once for 28 days. The control animals were administered vehicle only. The drug 
was administered orally by using oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study.  
Food and water Consumption: 
  Food and water consumed per animal was calculated for control and the treated 
dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 










All the animals were sacrificed by excessive anesthesia on day 29. Necropsy of 
all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
               Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten paraffin 
at 50°C and then in a cubical block of paraffin made by the “L” moulds. It was followed 
by microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemistry were subjected to One-way ANOVA followed by 
dunnet t test using a computer software programme – Graph pad version 7. All data 










Repeated Dose 28- day oral toxic study of KANA NEI 
 
Table 7: Body weight of wistar albino rats group exposed to KANA NEI 
 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 





1 6 14 21 28 
CONTROL 56.4 ± 2.34      
56.2±1.07 
56.7±1.30 56.8±1.10 56.4±1.70 
LOW DOSE 63.6±1.81 63.6±2.43 63.6±1.72 63.7±2.36 63.7±1.30 
MID DOSE 64.2±2.21 64.2±1.21 64.1±2.52 64.4±1.42 64.4±1.74 
HIGH 
DOSE 
58.2±3.40 58.2±1.42 58.4±1.44 58.6±1.78 58.8±2.62 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 




1 7 14 21 28 
CONTROL 282.2±05.64  282.2 ± 10.04 282.4 ± 12.40 
282.4± 
14.40 
282.2 ± 12.10 
LOW DOSE 280.7 ± 57.75 280.4 ± 4.19 281.3± 5.21 282 ±1.40 282.6± 6.16 
MID DOSE 281.1± 1.22 281.2 ± 2.21 281.2 ± 1.42 
282.2 ± 
5.08 
282.4 ± 13.12 
HIGH DOSE 275.2± 2.41 275.4±3.17 275.8 ± 2.64 
276.2 ± 
4.18 
277 ± 3.30 
P value (p)* NS NS NS NS NS 
 
 










2 7 23 22 28 
CONTROL 61±3.01 61.2±2.11 61.4±3.11 61.4.2±3.42 61±3.40 
LOW DOSE 59.5±7.12 59.5±1.44 59.6±1.50 59.4±1.20 59.8±1.92 
MID DOSE 60.2±6.70 60.2±2.20 60.6±2.24 60.6±1.46 60.7±1.74 
HIGH DOSE 64.3±1.55 64.6±1.54 64.8±2.16 65.1±1.50 65.1±1.72 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test 
 
Table 10: Haematological parameters of Wistar albino rats group exposed to 
KANA NEI 
 
Category Control Low dose Mid dose High dose P 
value 
(p)* 
Haemoglobin(g/dl) 34.6±0.43 34.6±0.30 34.6±0.13 34.6±0.23 N.S 
Total WBC (×103   l) 9.1±0.40 9.12±0.01 9.1±0.08 9.13±1.30 N.S 
Neutrophils (%) 15.1±0.20 15.12±0.23 15.13±1.06 15.14±1.07 N.S 
lymphocyte (%) 80.10±1.36 80.10±1.20 80.12±1.24 81.20±1.34 N.S 
Monocyte (%) 0.01±0.02 0.01±0.01 0.01±0.04 0.01±0.03 N.S 
Eosinophil (%) 0.04±0.06 0.04±0.03 0.04±0.05 0.04±0.07 N.S 
 
 




Platelets cells103/µl 1400.1±1.08 1400.3±4.84 1400.2±4.60 1400.4±6.32 N.S 
Total RBC 106/ µl 9.32±0.64 9.32±0.652 9.65±0.08 9.66±0.05 N.S 
PCV% 34.60±0.8 34.63±6.23 34.6±1.31 34.8±8.22 N.S 
MCHC g/dL 35.2±1.42 35.4±1.22 35.6±1.52 35.8±1.23 N.S 
MCV fL(µm3) 54.8±1.21 54.8±1.20 54.6±1.11 54.7±1.10 N.S 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 









GLUCOSE (R) (mg/dl) 85.10±1.22 85.13±1.31 85.6±.04 85.7±6.20 N.S 
T.CHOLESTEROL(mg/dl) 105.10±3.10 105.15±2.20 105.10±1.17 105.11±13 N.S 
TRIGLY(mg/dl) 76.03±1.04 76.04±1.32 76.05±1.32 76.06±1.04 N.S 
LDL 69.2±4.13 69.4±1.45 69.3±1.23     69.4±2.22 NS 
VLDL 14.6±1.30 14.6±1.42 14.6±1.22 14.4±1.24 NS 
HDL 24.12±2.30 24.12±2.30 24.16±1.42 24.65±1.34 NS 
Ratio 1(T.CHO/HDL) 5.1±1.10 5.1±1.20 5.1±1.30 5.1±1.60 NS 
Ratio 2(LDL/HDL) 
 
2.85±2.13 2.85±1.20 2.85±2.20 2.85±04.02 NS 
Albumin (g/dL) 
3.2±0.10 3.2±0.64 3.2±4.80 3.3±3.24 NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
 






Table 12: Renal function test of of Wistar albino rats group exposed to KANA 
NEI 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 22.11±0.10 22.10±0.15 22.16±1.22 22.12±1.63 N.S 
CREATININE(mg/d
l) 
0.6±0.02 0.6±0.03 0.6±0.05 0.6±0.09 N.S 
BUN(mg/dL) 27.5±0.03 27.5±0.14 27.8±0.30 27.8±1.40 NS 
URIC ACID(mg/dl) 6.04±0.02 6.1±0.20 6.1±0.30 6.2±0.60 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 











0.07±0.07 0.07±0.02 0.07±0.04 0.07±0.01 N.S 
SGOT/AST(U/L) 132.1±1.33 132.2±0.32 132.4±1.33 132.6±1.43 N.S 
SGPT/ALT(U/L) 99.10±1.44 99.14±1.10 99.24±1.64 99.23±0.20 N.S 
ALP(U/L) 182.40±1.12 182.2±1.14 183±1.24 184.3±2.51 N.S 
T.PROTEIN(g/dL) 6.5±0.13 6.5±0.21 6.7±0.32 6.7±0.34 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
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             KANA NEI BRONCHODILATOR ACTIVITY 
 
Bronchodilator Activity of Kana nei on Milk induced Leucocytosis and 
Eosinophilia method in mice model. 
After injected of milk (4 ml/kg) to mice significant increases (P value less than 
0.001) in leucocytes and eosinophils count in milk intoxicated disease control group. 
After the treatment Kana nei 100 and 200mg/kg exhibited significant reduction (P value 
less than 0.05) of leucocytes and eosinophils counts in mice. 
Table.1: Effect of Kana nei on milk-induced Leukocytosis and Eosinophilia in 
mice 
Group Dose Difference in no. of 
leucocytes (cu/mm) 
Difference in no. of 
eosinophils 
(cu/mm) 
1.Normal control Distilled water, 1 ml 95±13.26 29.12±3.34 
2. Disease control Milk, 4 ml/kg 4214±111.13 145.31±9.33 
3. Kana nei 100mg/kg 3426±88.75 120.56±16.34 
3. Kana nei 200 mg/kg 2334±67.45 105.42±5.6 
4. Dexamethasone 50 mg/kg 1967±142.45 60.24±4.62 
 
 Note: Values are expressed in mean ± SEM. N = 6. Comparison was done by one 
way ANOVA followed by Tukey – Kramer Multiple comparisons test where q value is 




































































































Mast cell stabilizing effects of  Kana nei  on ova albumin- induced mast cell 
degranulation in mice model: 
Table No.2: Effect of Kana nei on mast cell degranulation in mice 
Group Dose 
% Degranulation of mast cell 
1. Control – Distilled water 1 ml 
77.62 ±3.46 
2. Standard- sodium chromoglycate 50 mg/kg 
24.16±2.12 
3. Kana nei 100mg/kg 
36±4.65 
4. Kana nei 200mg/kg 
51.52 ± 2.21 
Note: Values are expressed in mean ± SEM. N = 6.  
 
Discussion:  
  Increased level of Leucocytes and eosinophils counts in our respiratory system 
play a vital role to induce bronchial hypersensitivity and produces airway 

























 MATERIALS AND METHODS 
Approval of the Screening committee and Institutional ethical committee (IEC) 
were obtained for undertaking the present study.  Institutional Ethical Committee 
(IEC) approval number is: GSMC-CH-ME-2/017/2017 
SELECTION OF PATIENTS: 
 The present study covers both male and female children of pediatric age groups. 
All cases were Carefully and thoroughly examined. Those who fulfilled the criteria of 
Sooli kanam according to the Clinical features in Siddha and modern reviews were 
selected with the aid of questionnaire. The opinion of Faculties of department was 
obtained and detailed history was recorded in the proforma of case sheet.  
The study design and the underlying hypothesis and the rights to withdraw from 
the study at any time were informed orally and in writing to all the participants. A Single 
arm open clinical trial was undertaken in OPD of PG department of Kuzhanthai 
maruthuvam, Government Siddha medical college attached with Arignar Anna Hospital 
of Indian Medicine and Homoeopathy, Arumbakkam, chennai-106 for a period of one 
year. 40 patients who fulfilled the inclusion criteria were included for the study.  
CLINICAL STUDIES: 
After finishing the toxicity studies 40 cases were selected from the OPD of 
Kuzhanthai maruthuvam Department, Arignar Anna Hospital of Indian Medicine and 
Homoeopathy, Arumbakkam, chennai-106. They were treated with the trail drug Kana 
Nei and observed for prognosis clinically.  
STUDY DESIGN & CONDUCT OF THE STUDY:  
 Study Type: An Open Clinical Trail  
StudyPlace: Arignar Anna Hospital of Indian Medicine and Homoeopathy,  
Arumbakkam, Chennai – 600 106.   
Study Period: 12 months after completion of preclinical studies.  
Sample size:   40 patients.  





Treatment period:  21 days 
POPULATION AND SAMPLE:  
1. Population consist of paediatric patients attending the OPD of Arignar Anna 
Hospital, GSMC, Chennai-106  
2. The sample consist of patients 3 – 12 years age group fulfilling all the inclusion 
criteria and exclusion criteria. 
STUDY PARTICIPANTS:  
INCLUSION CRITERIA:  
1. Age 3 to 12 years  
2.  Cough without expectoration  
3.  Dyspnea  
4.  Chest tightness  
5.  Wheezing  
6.  Decreased physical activity  
7.  Poor diet intake  
 EXCLUSION CRITERIA:  
      1.Childhood TB  
      2. Hypersensitivity Pneumonitis  
      3. Lung abscess   
      4. Cystic fibrosis  
      5. Bronchiolitis 
  
 WITHDRAWAL CRITERIA:  
      1.If any adverse reactions & altered symptoms occurred during the drug  
trial.  
      2.Intolerance to the drug.   




3.Patient turned unwilling to continue in the course of clinical trial.  
      4.Occurrence of any serious illness. 
ASSESMENT AND INVESTIGATION:  
CLINICAL ASSESMENT:  
• Cough without expectoration  
• Dyspnoea 
• Running nose  
• Chest tightness  
• Wheezing  
• Decreased physical activity  
• Poor diet intake 
SIDDHA DIAGNOSIS WAS MADE WITH THE HELP OF FOLLOWING 
METHODS: 
❖ Poriyalarithal  
❖ Pulanalarithal  
❖ Vinathal  
❖ Ennavagaithervugal (Including neerkuri, neikuri)  
❖ Udalthathukkal  
❖ Paruvakaalam (Season)  
❖ Thinaigal  
❖ Mukkutram  
LAB INVETIGATION:  
1,Blood:  
                       TC                                                    
 Differential WBC count  
    Neutrophils   
Lymphocytes    
Eosinophils   




Monocytes    
Basophils   
   2.ESR  
½ hr&   1 hr   
3.Hb 
4. Urine analysis : 
 Albumin 
 Sugar 
 Deposits  
SPECIFIC INVESTIGATION:  
1.Absolute Eosinophil count.  
METHODOLOGY OF TREATMENT 
 STUDY ENROLMENT:  
  Patients reporting at the OPD associated with clinical features of cough with 
expectoration, dyspnea, wheezing, chest tightness, running nose, decreased physical 
activity, poor diet intake are chosen for enrollment based on the inclusion criteria. The 
patient who are enrolled are informed about the study trail drug, possible outcomes of 
the study in the language and terms understandable to them and the informed 
consent/Assent would be obtained from the patient/patient’s parent using 
consent/assent form.  
CONDUCT OF THE STUDY:     
The trail drug will be given in the OPD department of  kuzhanthai maruthuvam, 
GSMC, Chennai. The patients will be asked to have a regular follow up in the OPD 
once in a 5days. In each and every visit the clinical assessment will be recorded in the 
prescribed proforma. The laboratory investigation will be done before and after 
treatment and recorded in the prescribed format.  





DATA COLLECTION FORMS:  
 Required information will be collected from each patient by using following 
forms.      
 Form I:    Screening and selection proforma  
            Form II:    History taking proforma  
      Form III:   Clinical assessment proforma  
       Form IV:   Clinical assessment during and after trial  
       Form V:    Laboratory Investigation proforma  
       Form VI:   Informed consent/Assent form  
       Form VII:  Withdrawal form  
       Form VIII: Patient information sheet  
DATA ANALYSIS:  
              After enrolling the patients in the study a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patient visits OPD 
during the study period necessary entries will be made in the assessment forms. The 
data entries and adverse events if any will be monitored by the Head of the Department.  
OUTCOME OF TREATMENT  
Primary Outcome:  
              Primary outcome is mainly assessed by comparing the reduction of symptoms 
by scoring before and after treatment.  
Secondary Outcome:  
Secondary outcome is assessed by comparing the safety parameters before and 
after treatment.  
 





ADVERSE EFFECT AND SERIOUS EFFECT MANAGEMENT:  
             If the trial patient develops any adverse reactions the patient will be referred to 
the Pharmacovigilance department of SCRI, CHENNAI and documented. For any 
adverse effect the investigator will give the proper management in the OPD.  
ETHICAL ISSUES  
 1. Informed consent/Assent will be obtained from the patient/patient’s parent or 
guardian after explaining about the clinical trial in an understandable language. 
 2. After the consent/Assent of the patient or patients parent (through consent/Assent 
form) if they fit in the criteria they will be enrolled in the study.  
 3. Treatment will be provided free of cost.  
 4. The patients who are excluded (as per the exclusion criteria) will be referring to 
OPD.  
ANALYSIS OF TRIAL MEDICINE:  
        1. The acute and subacute toxicity study was carried out in C.L.Baid Metha 
College of Pharmacy, Thoraipakkam, Chennai-97 
        2. The pharmacological analysis of trial drug for Bronchodilator activity was 
carried out in C.L.Baid Metha College of Pharmacy, Thorraipakkam, Chennai-97 
        3. The physiochemical and Phytochemical analysis of trialdrug was performed in 
Nobel research solution, kolathur, Chennai - 99 
        4. Biochemical analysis of the trial drug was performed in GSMC, Chennai-106 
  
 




      
       RESULTS AND OBSERVATIONS: 
 40 patients with confirmed diagnosis of soolikanam with satisfying the 
inclusion criteria wear enrolled after obtaining written informed consent and were to 
receive “KANA NEI” with dosage of 3 - 5 years 1gm  & 6- 12 years- 2 gms  twice daily 
for 21 days.  
Results were observed with respect to the following criteria:  
     1. Age  
     2. Sex 
     3.Religion distribution 
     4. Family history 
     5. Diet history 
     6. Parents socio economic status 
     7. Paruva kaalangal 
     8. Mukkutram 
     9. 7 Udal kattugal 
10.Envagai thervugal   
11. Neikuri  
12. Aetiological factors  
13. Clinical features  
14. Results  
            15. Investigation profile 
 
 








       
           AGE                                                   
   NO. OF 
CASES
     (OUT OF 40) 
 
PERCENTAGE 
    1      1    to   3  Years 
 
               7          17.5 % 
    2      4    to   6  Years 
 
              11          27.5 % 
    3      7    to  10 Years 
 
              17          42.5 % 
    4     11   to  12 Years 
 
               5           12.5 % 
 
             
 
INFERENCE:  
Out of 40 cases 17.5% of cases belong to age group 1-3 years,   27.5  % of cases  
belong to age group of 4-6 years, 42.5   % of cases belong to age group of 7-10  





1-3 YEARS 4-6 YEARS 7-10 YEARS 11-12 YEARS
1 2 3 4
percentage







S.NO SEX NO. OF CASES PERCENTAGE 
1 MALE CHILD 27 67.5% 
2 FEMALE CHILD 13 32.5% 
 
 
















No . Of cases Percentage
No . Of cases, 
27
67.5%
No . Of cases, 
13
32.5%
1 Male child 2 Female child







S.NO RELIGION NO OF CASES PERCENTAGE 
1 HINDU 35 87.5% 
2 MUSLIM 4 10% 




                
 
INFERENCE:  















S.NO FAMILY HISTORY NO OF CASES PERCENTAGE 
1 POSITIVE 23 57.5% 















0 10 20 30 40 50 60 70
NO OF CASES
PERCENTAGE
2 Negative family h/o 1 positive family h/o







S.NO DIET HISTORY NO OF CASES PERCENTAGE 
1 VEGETARIAN 12   30% 
2 MIXED 28   70% 
 
 
                   
 
INFERENCE: 

















NO OF CASES PERCENTAGE
VEGETARIAN MIXED











1 LOW INCOME GROUP 20 50% 
2 MIDDLE INCOME GROUP 14 35% 
 HIGH INCOME GROUP 6 15% 
     
 
                
 
INFERENCE: 
     According to this study 20 cases (50%) belongs to the low income group, 14 cases 
(35%) belongs to the middle income group and 6 cases (15%) belongs to high income 











LOW INCOME GROUP MIDDLE INCOME GROUP HIGH INCOME GROUP
1 2 3
NO OF CASES PERCENTAGE




7.DISTRIBUTION OF PARUVA KAALANGAL: 
S.NO PARUVA KAALANGAL NO OF CASES PERCENTAGE 
1 KAAR KAALAM 
(Mid AUG – Mid OCT) 
         1        2.5% 
2 KOOTHIR KAALAM 
(Mid OCT- Mid DEC) 
         4        10% 
3 MUNPANI KAALAM 
(Mid DEC- Mid FEB) 
        31        77.5% 
4 PINPANI KAALAM 
(Mid FEB- Mid APR) 
         4         10% 
5 ELAVENIL KAALAM 
(Mid APR- Mid JUN) 
          -           - 
 
6 MUDHUVENIL KAALAM 
(Mid JUN- Mid AUG) 
          -           - 
 
                     
INFERENCE: 
         Out of 40 cases   77.5 % of cases came during Munpanikaalam, 10% of cases of 
the incidence come under the Koothirkaalam &Pinpanikaalam and 2.5% cases of the 


























DERANGEMENT OF VATHAM: 
S.NO TYPES OF VATHAM NO OF CASES PERCENTAGE 
1 PRANAN          40           100% 
2 ABANAN           3            7.5% 
3 VIYANAN          15            37.5% 
4 UTHANAN          40            100% 
5 SAMANAN          40            100% 
6 NAAGAN          15             37.5% 
7 KOORMAN           0                0 
8 KIRUKARAN          40             100% 
9 DEVATHATHAN          10               25% 
10 DHANANJEYAN           0               0 
 
                         
 
INFERENCE: 
        According to this Pranan, Uthanan, Samanan and kirukaran has 100 %, viyanan & 
Naagan has 37.5% and Devathathan have percentage of 25%.  Abanan have lowest 



























DERANGEMENT OF PITHAM: 
 
S.NO TYPES OF PITHAM NO OF CASES PERCENTAGE 
1 ANILA PITHAM          27          67.5% 
2 RANJAGA PITHAM          18          45% 
3 SAATHAGA PITHAM          29          72.5% 
4 PIRASAGA PITHAM           4          10% 
5 AALOSAGA PITHAM           0            0 
 
                
 
INFERENCE: 
 According to this, Saathagam has 72.5%, Analagam has 67.5 %, Ranjagam  























DERANGEMENT OF KABAM: 
 
S.NO TYPES OF KABAM NO OF CASES PERCENTAGE 
1 AVALAMBAGAM         40          100 
2 KI LETHAGAM         30           75 
3 POTHIGAM          0            0 
4 THARPAGAM          0            0 
5 SANTHIGAM          0            0 
 
 
                          
 
INFERENCE: 





















9. 7 UDAL KATTUKAL: 
S.NO 7UDAL KATTUKAL NO OF CASES PERCENTAGE 
1 SAARAM        40        100% 
2 SENNEER        20         50% 
3 OON        15         37.5% 
4 KOZHUPU        20         50% 
5  ENBU         0          0 
6 MOOLAI         0                                 0 
7 SUKILAM/ 
SURONITHAM 
        0                                 0 
 
                    
 
INFERENCE: 
 In 7 Udalkattugal 42% of the cases had derangement in Saaram, 21% of cases 





















NO OF CASES PERCENTAGE 
1 NAA          18            45% 
2 NIRAM           5            12.5% 
3 MOZHI           4             10% 
4 VIZHI           0              0 
5 SPARISAM          18             45% 
6 NAADI                   
A KABA PITHAM           8             20% 
B VATHA KABAM          30             75% 
C PITHA KABAM           2              5% 
7 MALAM           5             12.5% 
8 MOOTHIRAM           0                0 
 
                               
INFERENCE: 
 In Envagaithervugal, Naa and Sparisam were affected in 45% of cases, Niram 
affected in 12.5% of cases, Mozhi affected in 10% of cases, Vathakabam affected in 
75% of cases, Kabapitham affected in 20% of cases and Vathapitham affected in 5% of 
































1 VATHANEER SPREAD LIKE 
SNAKE 
          4         10% 
2 PITHANEER SPREAD LIKE 
RING 
          4         10% 
3 KABANEER SPREAD LIKE 
PEARL 
         32        10% 
 
 
                
 
INFERENCE: 
 Vaathaneer, Pithaneer was observed in 10% of cases and Kabaneer was 
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PERCENTAGE
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12.AETIOLOGICAL FACTORS OF SOOLI KANAM: 
 
S.NO AETIOLOGICAL FACTOR NO OF CASES PERCENTAGE 
1 CLIMATIC CHANGES            8           20% 
2 RESPIRATORY INFECTION            5           12.5% 
3 FAMILY H/O OF ALLERGIC 
DISEASES 
         15           37.5% 
4 AGGRAVATED  FACTORS 
LIKE INHALED 
ALLERGENS, COOL 
BEVERAGES & ICE 
CREAMS 
         12            30% 
 
                    
INFERENCE: 
 From the above table the climate changes are about 20%. 12.5% of cases have 
a respiratory infection. 30%of cases have Aggravating factors like inhaled allergens, 
cool beverage & ice creams and 37.5% of cases have Family history of allergic diseases. 





































 BEFORE  
 TREATMENT  







1 WHEEZING    40   100%     4     10% 
2 COUGH    35    87.5%     3       7.5% 
3 RUNNING NOSE    20    50%     2     5% 
4 CHEST 
THIGHTNESS 




   19    47.5%     1       2.5% 
6 POOR INTAKE    26    65%      6     15% 
                                                  ASSOCIATED SYMPTOMS 
7 SNEEZING    15     37.5%       0       0 
8 FEVER    3     7.5%       0       0 
9 PALLOR    18     45%       4       10% 
10 SHORTNESS OF 
BREATHE 
    5     12.5%       2 
 
      5% 






                
 
INFERENCE: 
 Major clinical symptoms reported to be Wheezing (100%) after treatment it was 
reduced to 10%. 87.5% of cases had cough before treatment, after treatment it was 
reduced to 7.5%. 50% of cases had running nose, it was reduced to 5%.47.5% of cases 
had decreased p  hysical activity, it was reduced to 2.5%. 65% of cases had poor diet 
intake, it was reduced to 15%. 57.5% 0f cases had chest tightness, it was reduced to 























































Sneezing Fever Pallor Shortness
of breath
1 2 3 4 5 6 7 8 9 10
CLINICAL FEATURES
Before treatment After treatment







S.NO RESULTS NO OF CASES PERCENTAGE 
1 GOOD 31 77 
2 MODERATE 5 13 
3 POOR 4 10 
 
 
                       
 
INFERENCE: 
 77% of cases showed good results and 13% of cases showed moderate 
















  Parameter for assessment of bronchial asthma: 




 Parameters                        Scores 
1 Breathelessness Mild (1) Moderate 
(2) 
Severe (3) Absent (0) 














flaring up of 
alae nasi (3) 
Absent 
  (0) 






















  (0) 
5 Pulse/min <100 (1) 100-200 
(2) 
>120 (3) Normal 
  (0) 





  (0) 
7 Symptoms ≤2/weeks (1) >2/weeks 
     (2) 
Continues 
    (3) 
Abesnt 
  (0) 
 
 






Minimum score – 0     &    Maximum score is 21 
0 – Normal, 1 – 7 Mild, 8 – 14 Moderate, 15 – 24 Severe 














 1 8402 8/FC   12  0 
 2 7517 10/FC  15     8 
 3 8512 12/MC  14  0 
 4 9593 10/MC  7  0 
 5 1568 12/MC  15  4 
 6 3159 10/MC  7  0 
 7 2953 3/MC  9  0 
 8 9594 7/FC  7  0 
 9 4257 5/FC  15  0 
 10 4620 6/MC  12  0 
 11 4762 12/MC  8  0 
 12 5517 5/FC  8  0 
 13 5805 8/MC  9  0 
 14 5945 4/MC  16  0 
 15 6063 10/MC  14  0 
 16 6798 11/MC  8  0 
 17 7089 7/MC  13  2 
 18 7315 5/FC  10  0 
 19 7675 5/MC  8  0 




 20 7495 8/MC  8   0 
 21 1737 11/FC  11  2 
 22 5242 4/MC  9  0 
 23 5224 9/FC  8  0 
 24 6340 7/MC  17  0 
 25 6847 10/MC  8  0 
 26 7043 6/FC  24  10 
 27 8052 8/MC  7  0 
 28 8051 9/MC  11  4 
 29 9080 4/MC  13  6 
 30 9105 4/FC  9  0 
 31 9118 7/MC  14  0 
 32 594  3/FC  16  0 
 33 1683 3/MC  11  5 
 34 3229 8/FC  9  0 
 35  3827 3/MC  12  2 
 36 3607 7/MC  11  1 
 37 3973 12/MC  11  0 
 38 4336 10/FC  7  0 
 39 4662 6/MC  11  0 
 40 7603 3/MC  7  0 



























1 8402  Nithila 8/FC 09.10.18 Good 
2 7517 Varshini 10/FC 03.12.18 Good 
3 8512 Arun 12/MC 05.12.18 Good 
4 9593 Nareshkumar 10/MC 08.12.18 Poor 
5 1568 Mohan 12/MC 13.12.18 Good 
6 3159 Karthikeyan 10/MC 14.12.18 Good 
7 2953 Hariharasudan 3/MC 17.12.18 Good 
8 9594 Idhayasri 7/FC 18.12.18 Good 
9 4257 Ananya 5/FC 21.12.18 Moderate 
10 4620 Rithikeshwaren 6/MC 22.12.18 Good 
11 4762 Ashwagh 12/MC 22.12.18 Good 
12 5517 Gowsalya 5/FC 24.12.18 Moderate 
13 5805 Lingesh 8/MC 25.12.18 Good 
14 5945 Saran 4/MC 26.12.18 Good 
15 6063 Danush 10/MC 26.12.18 Good 
16 6798 Aathil 11/MC 27.12.18 Good 
17 7089 Varun 7/MC 28.12.18 Poor 
18 7315 Mokshitha 5/FC 28.12.18 Good 
19 7675 Dakshan 5/MC 29.12.18 Good 
20 7495 Ganesh 8/MC 29.12.18 Good 
21 1737 Kayalvizhi 11/FC 10.01.19 Good 
22 5242 Hemanth kumar 4/MC 23.01.19 Moderate 
23 5224 Fathu muthu 9/FC 23.01.19 Good 
24 6340 Thaveesh 7/MC 26.01.19 Good 
25 6847 Dhanush 10/MC 28.01.19 Good 





27 8052 Sagar 8/MC 30.01.19 Good 
28 8051 Syed afrose 9/MC 30.01.19 Poor 
29 9080 Vinith 4/MC 02.02.19 Moderate 
30 9105 Lafitha 4/FC 02.02.19 Good 
31 9118 Aakash 7/MC 02.02.19 Good 
32 594  Kanishka 3/FC 06.02.19 Good 
33 1683 Rushan shiva 3/MC 09.02.19 Good 
34 3229 Priya 8/FC 14.02.19 Good 
35 3827 Mithran 3/MC 15.02.19 Poor 
36 3607 Ramesh 7/MC 15.02.19 Good 
37 3973 Sheshan 12/MC 16.02.19 Moderate 
38 4336 Lathika 10/FC 17.02.19 Good 
39 4662 Vishnu 6/MC 18.02.19 Good 





























AEC ESR Hb 
  BT AT BT AT BT AT  
   







1 8402 8/FC 5100 40 50 10 6800 50 46 6 510 408 14 22 5 15 10 12.1 
2 7517 10/FC 10400 70 25 5 11500 64 32 4 520 460 5 15 3 8 13.5 13 
3 8512 12/MC 6750 47 43 10 12000 54 40 6 675 720 7 18 3 8 13.3 12 
4 9593 10/MC 9800 62 33 5 12000 66 31 3 490 360 16 25 8 10 12.7 13 
5 1568 12/MC 5100 58 33 9 7500 60 35 5 495 375 20 38 10 15 11.2 13 
6 3159 10/MC 9800 60 35 5 11000 64 34 3 490 330 18 36 12 24 13 13 
7 2953 3/MC 5400 52 39 9 9000 59 37 4 486 360 5 15 5 10 13.2 13 
8 9594 7/FC 6500 65 30 9 10500 64 33 3 585 315 15 25 10 20 12.6 12 
9 4257 5/FC 8500 47 46 7 9000 55 40 5 595 450 5 16 5 10 11.8 12  
10 4620 6/MC 5400 65 27 8 12000 63 35 2 432 240 3 5 5 10 13.7 14  
11 4762 12/MC 9900 65 31 4 10200 69 30 1 396 120 4 10 2 4 14.7 14  
12 5517 5/FC 5800 56 34 10 10500 60 36 4 580 420 15 35 10 20 9.7 12  
13 5805 8/MC 4400 51 39 10 5100 59 39 6 440 306 5 15 5 10 11.4 13  




15 6063 10/MC 7600 55 36 9 9500 54 41 5 684 475 7 8 5 10 12.3 12  
16 6798 11/MC 5400 46 46 8 8500 68 30 4 432 340 5 15 5 9 12.8 13  
17 7089 7/MC 9030 46 47 7 9300 60 35 5 632 465 26 42 8 16 12.3 13  
18 7315 5/FC 8100 52 42 6 8000 60 38 4 486 392 4 7 5 10 12.1 12  
19 7675 5/MC 6510 64 28 8 11500 60 35 5 520 575 7 18 5 10 12.3 13.5  
20 7495 8/MC 9300 56 39 5 11100 60 38 3 465 333 4 10 5 10 13.5 13.5  
21 1737 11/FC 6100 68 26 6 6100 61 35 4 366 244 13 22 5 8 12.7 11.3  
22 5242 4/MC 6300 40 51 9 9000 60 35 5 567 450 7 8 5 10 11.5 12  
23 5224 9/FC 4800 44 48 8 9800 65 33 2 384 294 15 26 10 20 12.1 13  
24 6340 7/MC 9500 67 27 6 10900 68 38 4 570 436 2 5 5 10 14.5 13.5  
25 6847 10/MC 7600 55 36 9 6000 60 38 2 684 120 7 18 5 10 12 13  
26 7043 6/FC 11700 74 21 5 10500 65 38 4 585 420 7 15 5 10 13 12  
27 8052 8/MC 6500 58 34 8 8500 65 33 4 520 340 4 12 5 10 11.6 13  
28 8051 9/MC 8500 56 37 7 8000 64 35 6 595 505 6 12 5 10 13 12  
29 9080 4/MC 5900 40 51 9 10400 65 33 4 531 416 5 15 3 12 10.5 12  
30 9105 4/FC 6500 37 33 8 9000 60 38 5 520 450 5 15 4 8 13.1 12  
31 9118 7/MC 9100 61 33 6 9000 60 36 4 546 360 5 12 4 8 11.9 12  
32 594 3/FC 11600 65 30 5 14000 65 33 3 580 420 15 25 5 10 13.2 14  




34 3229 8/FC 11500 68 28 4 11300 64 34 3 460 339 18 36 5 10 12.3 13  
35 3827 3/MC 8800 47 47 6 8000 65 33 4 528 320 3 10 5 10 11.1 12  
36 3607 7/MC 8500 60 32 8 9000 65 33 5 680 450 15 30 10 20 12 13.1  
37 3973 12/MC 4500 64 31 8 11000 66 32 3 360 303 8 18 5 10 13 13  
38 4336 10/FC 7500 62 28 10 12000 64 34 6 750 720 18 36 10 20 11.6 12  
39 4662 6/MC 8400 71 25 4 8000 70 28 4 336 320 13 22 10 20 12 13          
40 7603 3/MC 9200 65 29 6 11000 64 34 4 552 440 7 15 5 10 8.9 9  
BT - Before Treatment; AT - After Treatment; P - Polymorphs; L - Lymphocytes; E - Eosinophils;                  AEC - Absolute Eosinophil count; ESR - Erthrocyte sedimentation Rate;  







INVESTIGATION REPORT OF THE PATIENTS 














                    
                           URINE ANALYSIS 
 
 
       BEFORE 
TREATMENT 




Alb Sug Dep Alb Sug Dep 
1 8402  Nithila 8/FC NIL NIL NAD NIL NIL NAD 
2 7517 Varshini 10/FC NIL NIL NAD NIL NIL NAD 
3 8512 Arun 12/MC NIL NIL NAD NIL NIL NAD 
4 9593 Naresh kumar 10/MC NIL NIL NAD NIL NIL NAD 
5 1568 Mohan 12/MC NIL NIL NAD NIL NIL NAD 
6 3159 Karthikeyan 10/MC NIL NIL NAD NIL NIL NAD 
7 2953 Harihara sudan 3/MC NIL NIL NAD NIL NIL NAD 
8 9594 Idhayasri 7/FC NIL NIL NAD NIL NIL NAD 
9 4257 Ananya 5/FC NIL NIL NAD NIL NIL NAD 
10 4620 Rithikeshwaren 6/MC NIL NIL NAD NIL NIL NAD 
11 4762 Ashwagh 12/MC NIL NIL NAD NIL NIL NAD 
12 5517 Gowsalya 5/FC NIL NIL NAD NIL NIL NAD 
13 5805 Lingesh 8/MC NIL NIL NAD NIL NIL NAD 
14 5945 Saran 4/MC NIL NIL NAD NIL NIL NAD 
15 6063 Danush 10/MC NIL NIL NAD NIL NIL NAD 
16 6798 Aathil 11/MC NIL NIL NAD NIL NIL NAD 
17 7089 Varun 7/MC NIL NIL NAD NIL NIL NAD 
18 7315 Mokshitha 5/FC NIL NIL NAD NIL NIL NAD 
19 7675 Dakshan 5/MC NIL NIL NAD NIL NIL NAD 
20 7495 Ganesh 8/MC NIL NIL NAD NIL NIL NAD 
21 1737 Kayalvizhi 11/FC NIL NIL NAD NIL NIL NAD 
22 5242 Hemanthkumar 4/MC NIL NIL NAD NIL NIL NAD 





24 6340 Thaveesh 7/MC NIL NIL NAD NIL NIL NAD 
25 6847 Dhanush 10/MC NIL NIL NAD NIL NIL NAD 
26 7043 Meganethra 6/FC NIL NIL NAD NIL NIL NAD 
27 8052 Sagar 8/MC NIL NIL NAD NIL NIL NAD 
28 8051 Syed afrose 9/MC NIL NIL NAD NIL NIL NAD 
29 9080 Vinith 4/MC NIL NIL NAD NIL NIL NAD 
30 9105 Lafitha 4/FC NIL NIL NAD NIL NIL NAD 
31 9118 Aakash 7/MC NIL NIL NAD NIL NIL NAD 
32 594  Kanishka 3/FC NIL NIL NAD NIL NIL NAD 
33 1683 Rushan shiva 3/MC NIL NIL NAD NIL NIL NAD 
34 3229 Priya 8/FC NIL NIL NAD NIL NIL NAD 
35 3827 Mithran 3/MC NIL NIL NAD NIL NIL NAD 
36 3607 Ramesh 7/MC NIL NIL NAD NIL NIL NAD 
37 3973 Sheshan 12/MC NIL NIL NAD NIL NIL NAD 
38 4336 Lathika 10/FC NIL NIL NAD NIL NIL NAD 
39 4662 Vishnu 6/MC NIL NIL NAD NIL NIL NAD 
40 7603 Kishore 3/MC NIL NIL NAD NIL NIL NAD 
 








    DISCUSSION 
Sooli kanam is a pediatric disease, the clinical features of which are clearly 
described in various Siddha literatures. This disease most probably correlates with 
childhood bronchial asthma   
In this study 40 cases were treated at the post graduate Kuzhathai maruthuvam 
department. Siddha methods of diagnosis were carried out and recorded in the selection 
proforma, and the diagnosis was confirmed with the help of modern investigations. The 
patients were treated with the drug “ Kana Nei ” are clearly observed. The observations 
are discussed here under,  
1. DISTRIBUTION ACCORDING TO AGE:  
 This study indicates that children under the age group of 7 to 10  years 42.5% 
are mostly affected.  
  27.5% children are affected in the age group of 4 to 6 years.  
  17.5% children are affected in the age group of 1 to 3years. 
  12.5% children are affected in the age group of 11 to 12 years     
2. DISTRIBUTION ACCORDING TO SEX:  
  Among 40 cases, 27 cases (67.5% )were male children and 13 cases (32.5%) 
were female children.  
3.DISTRIBUTION ACCORDING RELIGION: 
 Among 40 cases 87.5% were Hindu. 
10% were Muslims. 
10% were Christian. 
4. FAMILY HISTORY:  
  According to family history 57.5% of the cases had positive family history and 
42.5% of the cases had no relevant family history. The highest incidence of cases had 






5. DIET HISTORY:  
  According to diet history high incidence of cases (70%) was noted in mixed 
diet and in vegetarian (30%) cases were noted.  
6. DISTRIBUTION ACCORDING TO SOCIO ECONOMIC STATUS:  
 Among 40 cases, maximum numbers of patients 50% were in low income 
group, 35% were in middle income group and 15% were in high income group.  
The highest incidence occurred in low income group. Because of poverty, 
malnutrition and unhygienic this disease is more prevalent among the poor. 
7. DISTRIBUTION ACCORDING TO PARUVA KAALANGAL :  
  Among the 40 cases, highest incidence 77.5% cases were observed in Munpani 
kaalam, 10% cases were observed in Pinpani kaalam and koothir kalam, 2.5% of cases 
were observed in Kaar kaalam.  
8. UYIR THATHUKKAL – VATHAM:  
  In vatham, all cases had affected in Pranan, Uthanan, Samanan and Kirukiran 
(100%). Viyanan and Naagan was affected in 37.5%, Devathathan was affected in 25%, 
Abanan was affected in 7.5%.    
 UYIR THATHUKKAL – PITHAM:  
  In pitham, Anilam was affected in 67.5% of cases.  
  45% of cases had affected in Ranjagam, 
  72.5% of cases had affected in Saathagam.  
  Pirasagam was affected  in 10% of cases.  
  UYIR THATHUKKAL – KABAM:  
  In Kabam, Avalambagam was affected in all patients (100%).  






9. 7 UDAL KATTUKAL:  
  Out of 40 cases 100% of the cases had affected in saaram.  
  50% of cases had affected in senneer and kozuppu 
  37.5 of cases had affected in oon.  
10. ENVAGAI THERVUGAL:  
 According to the study Naa and Sparisam were affected in 45% of cases.  
 mozhi affected in 25% of cases.  
 Niram affected in 10% of cases.  
             Vatha kabam affected in 75% of cases.  
 Kaba pitham affected in 20% of cases.  
 Pitha kabam affected in 5% of cases.  
11. NEIKURI :  
  Among 40 cases Kaba neer was observed in 80% of cases.  
  Vaatha neer, Pitha neer was observed in 10% of cases.  
12. AETIOLOGICAL FACTORS OF SOOLI KANAM :  
  Among the 40 cases 20% was caused by climatic changes.  
  12.5% of cases have a respiratory infection.  
  30% of cases have Aggravating factors like inhaled allergens, cool beverage 
& ice creams.  









13. CLINICAL FEATURES:  
 Major clinical symptoms reported to be Wheezing (100%) after treatment it 
was reduced to 10%. 87.5% of cases had cough before treatment, after treatment it was 
reduced to 7.5%. 50% of cases had running nose, it was reduced to 5%. 47.5% of cases 
had decreased physical activity, it was reduced to 2.5%. 65% of cases had poor diet 
intake, it was reduced to 15%. 57.5% 0f cases had chest tightness, it was reduced to 
2.5% & and most of other clinical signs were relieved after treatment.   
14. LAB INVESTIGATIONS:  
 Routine examination of blood and urine were done before and after treatment.  
 In most of the cases (100%) elevated ESR and Absolute Eosinophil count was 
decreased after treatment (90%).  
15. BIOCHEMICAL ANALYSIS:  
             Bio chemical analysis shows  
 Acid Radicals- Chlroide 
             Basic Radicals- Iron, Calcium, Starch, Reducing sugar are presents. 
16. PHARMACOLOGICAL ACTIVITY:  
 Pharmacological analysis showed the drug has significant Bronchodilator 
activity.  
 
 17. PHYSICO CHEMICAL ANALYSIS:  
 Viscosity at 50o c (Pa s)                  -   54.62 
 Refractive index                              -    1.44 
 Weight per ml (gm/ ml)                  -  0.073 gm/ml 





 Saponification value (mg                -  194.56 
 Of KOH to saponify 1gm of fat) 
 Acid value mg KOH/ g                   -    0.5049 
 Peroxidase value mEq/kg                -    4.063  
 
18. TOXICITY STUDY OF THE DRUG:  
  The acute and sub-acute toxicity study of the trial drug was carried out 
in Wistar albino rats reveals that the drug has no adverse effects, of it is safe to human 
being 
 
19. RESULT:  
   Satisfactory improvement was reported in 21 days of commencement of 
treatment. Out of 40 cases, 31 cases (77%) showed Good response and also remarkable 
relief of signs and symptoms.  
Moderate result was observed in 5 cases (13%) with reduction of signs and 
symptoms. In cases the result was poor 4 (10%) a there is no significant 
improvement of symptoms.  
 
20. STATISTICAL REPORT:  
   Since the p value is significant in all clinical features and also in absolute 
eosinophil count, So there is significant reducing of Absolute eosinophil count & 
clinical features among the patients for the treatment of Sooli Kanam (Childhood 








                                                    
                                               SUMMARY  
1. The aim of  the study is to assess the efficacy of  trial drug “KANA NEI” for 
“SOOLI KANAM (CHILDHOOD BRONCHIAL ASTHMA)” without any adverse 
effects. 
 2. The etiology, pathogenesis, signs and symptoms of Sooli kanam have been 
correlated with that of childhood bronchial asthma with evidence of literature.  
3. Clinical diagnosis and selection of cases based on clinical features described in 
Balavaagadam text book and also using questionnaire. 
 4. The internal medicine chosen for treatment and management of Sooli kanam was 
Kana nei 1g 3 -5 yrs & 2gm 6-12 yrs, twice a day, after food. 
 5. The trial drug selection based on its siddha pharmacological action to pacify the 
deranged vatham, pitham and kabam and also due to its, Bronchodilator and Anti 
histamine effect of the ingredients.  
6. 40 cases were diagnosed with Sooli kanam clinically observed for clinical diagnosis, 
laboratory diagnosis, Absolute eosinophil count during the treatment and the results 
were dealt in the proforma.  
7. Laboratory diagnosis was done by modern methods of examinations.  
8. The treatment covers administration of trial drug according to the age and also 
includes pranayamam.  
9. The documentation of observation made during the clinical study showed that the 
drug is clinically more effective.  
10.  The biochemical analysis Shows Acid Radicals- chloride and Basic Radicals- 
Iron, Calcium, Starch, Reducing sugar are present. 
11. Sterility test by pour plate method of Kana nei shows no growth / colonies like E-







12. In the pharmacological analysis, the trial drug Kana Nei had significant, 
Bronchodilator activity which controlling the airway hyper responsiveness help to 
improve the patients quality of life.  
13. The physico chemical analysis of the trial drug shows the Viscosity at 50o c (Pa s) 
- 54.6, Refractive index -1.44,Weight per ml (gm/ ml) -0.073 gm/ml, Iodine value (mg 
12/g)   - 97.155, Saponification value (mg of KOH to saponify 1gm of fat) -  194.56, 
Acid value mg KOH/ g -  0.5049, Peroxidase value mEq/kg - 4.063  , So it shows the 
safe and effectiveness of the drug. With these benefits of  KANA NEI is more effective 








               CONCLUSION  
Bronchial asthma is the most common chronic disabling disease of childhood 
as measured by school absences, emergency department visits and hospitalizations. 
Asthma is the leading chronic disease among children in most industrialized 
countries, Growing at an alarming rate, there is evidence that its prevalence has 
increased considerably over the past 20 years, especially in children. Its impact in 
reducing the quality of life in children.   
In this clinical study Kana Nei were taken as Internal medicine respectively. 
Sooli kanam (Bronchial asthma) occurs due to alteration in Kaba kutram. In Kana Nei 
most of the drugs have Kaarpu suvai, and it decrease the Kaba kuttram. Ghee based 
medicine nourishes the immune system and it increases appetite, overall helps to 
improve the Health. So I choose this drug and it is more effective to reduce the Kaba 
kuttram in Bronchial asthma.   
The treatment of Sooli kanam with Kana Nei has showed Good response with 
no adverse effect and ensure to be safe, effective and simple to administration. The 
drugs have Bronchodilator activity.  
Statistically it is concluded that the treatment was effective and  highly 
significant 
By using Scores, parameters for assessment of Bronchial asthma shows there is 
a significant difference between Before Treatment and After Treatment..  
Clinical results were found to be good improvement was found in 77 % of cases, 
moderate in 13% of cases and Poor in 10% of cases.  








           BIO STATISTIC REPORT 
 
TREATMENT FOR SOOLI KANAM (CHILHOOD BRONCHIAL ASTHMA): 
 
The most popular non parametric statistical tool namely, Paired Test 





Results of Statistical Analysis of subjective parameters observed Before and 
Afetr Treatment of 40 (n) patients of Sooli Kanam at Arignar Anna 




 S.NO Clinical features No of Before No of After P Value 
   cases Treatment cases Treatment   
    n%  n%   
        
 1 Wheezing 40 100% 4 10% P<0.000 
        
 2 Cough 35 87.5% 3 7.5% P<0.000 
        
 3 Running nose 20 50% 2 5% P<0.000 
        
 4 Chest tightness 23 57.5% 1 2.5% P<0.000 
        
 5 Decreased 19 47.5% 1 2.55 P<0.000 
  physical activities       
        
 6 Poor intake 26 65% 6 15% P<0.000 
        
 7 Sneezing 15 37.5% 0 0 P<0.000 
         
         
       147 
BIO STATISTIC  
 
 
8 Fever 3 7.5% 0 0 P<0.000 
       
9 Pallor 18 45% 4 10% P<0.000 
       
10 Shortness of 5 12.5% 2 5% P<0.070 
 breathe      
       
 
 
Paired t test, C.I : 95%  p<0.01 
 
Software : spss 21 version 
 




Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of sooli kanam 





Results of Statistical Analysis of Objective parameters observed Before and 
After treatment of 40 (n) patients of Sooli Kanam at Arignar Anna 
Hospital, Chennai-106. 
 
S.no Parameters  Mean Difference Paired p value Statistical 
      
t 
 
significance   Before  After   
  treatment Treatment  value  of 
        difference 
         
1 AEC 518  379 138.95 8.958 P<0.000 Significant 
















The Minimum value of Absolute eosinophil count is 336 before Treatment and 
after the intervention of the Kana Nei it was Reduced to 120. The Maximum value 
was Reduced from 750 to 720. 
 
Since the p value is <0.001, there is a significant difference between Before 
Treatment and After Treatment values. After the Intervention of Kana Nei, the mean 
of the Absolute eosinophil count is Decreased about 138.95 
 
The above findings (ie) Both the Clinical features and the Absolute eosinophil 
count shows that the P value is <0.001, hence we can reject the Null hypothesis and 
the above said results shows that there is a significant evidence seen in both the 
Clinical symptoms and Absolute eosinophil counts are decreased after the 
intervention of the Kana Nei. It shows that the drug Kana Nei is Highly significant 
for the Treatment of SOOLI KANAM (Childhood Bronchial Asthma). 
 
NULL HYPOTHESIS: There is no difference between the Two dependent 
group (Before and After Treatment). 
 
ALTERNATIVE HYPOTHESIS: There is a difference between the Two 
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Name and Address of the Researcher Dr.D.Jeevitha 
Government Siddha Medical College, 
Chennai, Tamil Nadu, India 
Sample –ID Kana Nei - KAN 
Parameter Requested  for Analysis Phytochemical Analysis 
Sample Received In Person 
Method of Analysis PLIM- Protocol – ASU Formulations 
Analysis Type Physicochemical Analysis  
Result of Analysis Test and Analytical Reports Attached As 
Annexures 
Phytochemical Analytical Report 
S.NO TEST OBSERVATION 
1 ALKALOIDS   
2 FLAVANOIDS   + 
3 GLYCOSIDES   + 
4 STEROIDS   + 
5 TRITERPENOIDS   + 
6 COUMARIN   + 
7 PHENOL   + 
8 TANIN   - 
9 PROTEIN   - 
10 SAPONINS   - 
11 SUGAR   + 
12 ANTHOCYANIN   - 
13 BETACYANIN   + 
 
+ -> Indicates Positive and - -> Indicates Negative 
               Noble Research Solutions     





Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations   
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 – 42691289 








Name and Address of the Researcher 
Dr.D.Jeevitha 
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 
Parameter Requested for Analysis 




Kana Nei - KAN 
Description of the Sample Liquid 
Method of Analysis                                                                                          
Instrument 
Extraction Solvent 
                                    
Model: AA 240 Series                                                                          
HCl and HNO3 
Analysis Type Third Party Analysis  
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HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for detecting 
metals and metalloids in environmental samples. The total heavy metal content of the sample 
was performed by Atomic Absorption Spectrometry (AAS) Model AA 240 Series. In order to 
determination the heavy metals such as mercury, arsenic, lead and cadmium concentrations in 
the test item. 
Sample Digestion 
Test sample was digested with 1mol/L HCl for determination of arsenic and mercury. 
Similarly for the determination of lead and cadmium the sample were digested with 1mol/L of 
HNO3. 
Standard reparation 
 As & Hg- 100 ppm sample in 1mol/L HCl 
 Cd & Pb- 100 ppm sample in 1mol/L HNO3 
 
Test Report 




Result Analysis Maximum Limit 
Mercury 253.7 nm BDL 1 ppm 
Lead 217.0 nm BDL 10 ppm 
Arsenic 193.7 nm BDL 3 ppm 
Cadmium 228.8 nm BDL 0.3 ppm 
BDL- Below Detection Limit 
 
Report and Inference 
 Results of the present investigation have clearly shows that the sample has no traces of 
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Name and Address of the Researcher 
Dr.D.Jeevitha 
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 





Kana Nei - KAN 




                                                             
CAMAG TLC SCANNER III 
Aluminium Coated Silica Gel – Merck 
Chloroform: Hexanel: Methanol(6:3:1) 
Analysis Type Third Party Analysis  
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       TLC Analysis  
 
 
HPTLC finger printing of Sample KAN 
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HPTLC finger printing analysis of the sample reveals the presence of four prominent peaks corresponds to 
presence of four versatile phytocomponents present with in it. Rf value of the peaks ranges from 0.31 to 
0.69.  Further the peak 3 and 4 occupies the major percentage of area of  46.63 and 28.35 % which 
denotes the abundant existence of such compounds.  
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Project ID NRS/AS/0339/02/2019 
Name and Address of the Researcher Dr.D.Jeevitha 
Government Siddha Medical College, Chennai 
Tamil Nadu, India 
Parameter Requested by the Customer for Analysis Organochlorine pesticides 
Organophosphorus pesticides 
Pyrethroids 
Sample Received In Person 
Sample –ID Kana Nei – KAN 
Description of the Sample Semi Solid 
Extraction Acetone and Toulene 
Analysis Type Third Party Analysis  
Result of Analysis Test Report Attached 
Extraction 
Test sample were extracted with 100 ml of acetone and followed by homogenization for brief 
period. Further filtration was allowed and subsequent addition of acetone to the test mixture. Heating of test 
sample was performed using a rotary evaporator at a temperature not exceeding 40ºC until the solvent has 
almost completely evaporated. To the residue add a few milliliters of toluene R and heat again until the 
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AYUSH Limit (mg/kg) 
I.Organo Chlorine Pesticides 
Alpha BHC BQL 0.1mg/kg 
Beta BHC BQL 0.1mg/kg 
Gamma BHC BQL 0.1mg/kg 
Delta BHC BQL 0.1mg/kg 
DDT BQL 1mg/kg 
Endosulphan BQL 3mg/kg 
II.Organo Phosphorus Pesticides 
 
 
Malathion BQL 1mg/kg 
Chlorpyriphos BQL 0.2 mg/kg 




Cypermethrin BQL 1mg/kg 
BQL- Below quantification Limit  
Result: The results showed that there were no traces of pesticides residues such as Organo chlorine, 
Organo phosphorus and pyrethroids in the sample provided for analysis.  
Reference 
1. WHO guideline for assessing the quality of herbal medicines with reference to contaminants and 
residues. WHO Geneva. 2007. 
2. Lohar. D.R. Protocol for testing of ASU medicines. Pharmacopoeial Laboratory for Indian Medicines. 
Ministry of AYUSH. 2007. 
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Project ID NRS/AS/0339/02/2019 
Name and Address of the Researcher Dr.D.Jeevitha 
Government Siddha Medical College, Chennai 
Tamil Nadu, India 
Parameter Requested by the Customer for Analysis Aflatoxin Assay By TLC (B1,B2,G1,G2) 
Sample Received In person 
Sample –ID Kana Nei - KAN 
Description of the Sample Semi Solid 
Analysis Type Third Party Analysis  













               Noble Research Solutions   
ISO 9001-2015 certified company  




                                               
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations   
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 – 42691289 






Aflatoxin B2  
Aflatoxin G1  
Aflatoxin G2 
Solvent 
Standard samples was dissolved in a mixture of chloroform and acetonitrile (9.8 : 0.2) to obtain a 
solution having concentrations of 0.5 µg per ml each of aflatoxin B1 and aflatoxin G1 and 0.1 µg per ml 
each of aflatoxin B2 and aflatoxin G2.  
Test solution: Concentration 1 µg per ml 
Procedure 
Standard aflatoxin was applied on to the surface to pre coated TLC plate in the volume of 2.5 µL, 5 
µL, 7.5 µL and 10 µL. Similarly the test sample was placed and Allow the spots to dry and develop the 
chromatogram in an unsaturated chamber containing a solvent system consisting of a mixture of 
chloroform, acetone and isopropyl alcohol (85 : 10 : 5) until the solvent front has moved not less than 15 cm 
from the origin. Remove the plate from the developing chamber, mark the solvent from and allow the plate 
to air-dry. Locate the spots on the plate by examination under UV light at 365 nm. 
 
Aflatoxin Sample KAN AYUSH Specification Limit 
B1 Not Detected - Absent 0.5 ppm 
B2 Not Detected - Absent 0.1 ppm 
G1 Not Detected - Absent 0.5 ppm 
G2 Not Detected - Absent 0.1 ppm 
Result: The results shown that there was no spots were been identified in the test sample loaded on TLC 
plates when compare to the standard , which indicates that the sample were free from Aflatoxin B1, 
Aflatoxin B2, Aflatoxin G1, Aflatoxin G2. 
Reference 
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Luciana de CASTRO. Determining Aflatoxins B1, B2, G1 And G2 In Maize Using Florisil Clean Up With 
Thin Layer Chromatography And Visual And Densitometric Quantification. Ciênc. Tecnol. Aliment. vol.21 
no.1 Campinas. 2001. 
 
FORMS 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
     ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
              CHENNAI – 600 106 
  POST- GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
                     AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD   
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
FORM l - SCREENING AND SELECTION PROFORMA  
1.OP NO:  .................................................................  
2. NAME:  ………………………………………….   
3. AGE:      ………       4.GENDER: ………….......  
5. F. OCCUPATION: ………………………………..     6.F. INCOME: ………. 
7. ADDRESS:    ……………………………………   
……………………………………  
……………………………………  
8. CONTACT NO:    ……………………………………  
 INCLUSION CRITERIA:  
▪ Age 3 to 12 years                            Yes/No            
▪ Cough without expectoration         Yes/No  
▪ Dyspnoea                                        Yes/No  
▪ Running nose                                  Yes/No          
▪ Chest tightness                                Yes/No                              
▪ Wheezing                                        Yes/No                             
▪ Decreased physical activity            Yes/No                            
▪ Poor diet intake                               Yes/No   
 
• Patients who are willing to sign the informed consent stating that she will 
conscientiously stick to the treatment during 21 days but can opt out of the trial of her 
own conscious discretion.    Yes / No  
 
 
EXCLUSION CRITERIA  
(Clinical history)  
▪ Childhood TB  
▪ Hypersensitivity Pneumonitis  
▪ Lung abscess   
▪ Cystic fibrosis  
▪ Bronchiolitis  
  
ADMITTED TO TRIAL:  








Date:         
Station:  








GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
     CHENNAI-600106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
FORM lI -HISTORY TAKING PROFORMA 
 
1. SERIAL NO OF THE CASE: …….          2.OP/IP NO: .............................. 
3. NAME: …………………………………     4. AGE: …….. 5. GENDER: ……..  
5. F. OCCUPATION: ………………………………      6.F. INCOME:  
7. COMPLAINTS& DURATION:    
  
8. PERSONAL HISTORY:  
  
9. HISTORY OF PREVIOUS ILLNESS  
  
  
10. BIRTH HISTORY  
  
11.DIETARY HABIT:    1. Vegetarian  
      2. Non-vegetarian  
12. FAMILY HISTORY:  
Whether this problem runs in family?  
  1. Yes                               2.No          
If yes, mention the relationship of affected person(s) ---------------------  
History of previous investigations if any ------------------------------  
  
Date:           
Station  
  




















    GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI-600106 
POST- GRADUATE DEPARTMENT OF KUZHANTHAI  MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
FORM III ASSESSMENT PROFORMA 
1. SERIAL NO: …………………    
2.OP / IP NO: ......................................    
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................             
  
GENERAL EXAMINATION:  
Height (cms)                 : ………………………….                    
Weight (kg)    : ………………………….                    
Temperature(°F)     : ………………………….                    
Pulse rate(/min)   : ………………………….                    
Heart rate(/min)   : ………………………….                    
Respiratory rate(/min)  : ………………………….                    
Blood pressure(mm/Hg)       : ………………………….            
              Present        /   Absent  




Pedal edema : 
Clubbing  : 
Jugular vein pulsation :  
SYSTEMIC EXAMINATION  
Cardiovascular System  : ………………………….  
                   
 Respiratory system   : ………………………….        
             
 Gastro-intestinal system  : ………………………….    
                 
 CentralNervous System  : ………………………….         
            
 Urogenital system   : ………………………….     
                
 Endocrine System   : ………………………….                    
  
SIDDHA SYSTEM OF EXAMINATIONS:  
1. THEGI:  [BODY CONSTITUTION]   
1. Vathaudal : 
2. Pithaudal : 
3. Kabaudal : 
4. Thonthaudal :    
2. NILAM:  [LAND WHERE PATIENT LIVED MOST]  
 1. Kurinji (Hilly terrain) :                                  
 2. Mullai (Forest range)  :                      
 3. Marutham  (Plains)  :                       
4. Neithal (Coastal belt) :                    
 5. Paalai (Arid regions) : 
3. KAALAM:  
1. Kaarkaalam   :                         4.Pinpani kaalam : 
2. Koothirkaalam :                       5. Ilavenilkaalam : 
3. Munpanikaalam :                     6.Muthuvenil kaalam : 
4. GUNAM:  
 1.Sathuvam :                             2.Raasatham :                       3.Thaamatham : 
5. IMPORIGAL (SENSORY ORGANS):  
                       Normal/Affected  
Mei :       -------------------------------------------  
Vaai :      -------------------------------------------  
Kann :     ------------------------------------------- 
Mukku :   ------------------------------------------ 
Sevi :        ------------------------------------------ 
6. KANMENDHIRIYAM (MOTOR ORGANS):  
Kai :         ---------------------------------               
Kal :         --------------------------------  
Vaai :       --------------------------------  
Eruvai :     -------------------------------- 
Karuvaai :  -------------------------------- 
 
 
7. KOSANGAL (SHEATH):  
Annamayakosam :    ------------------------  
Pranamayakosam :    --------------------------  
Manomayakosam :     -------------------------------  
Vignanamayakosam :   -----------------------------  
Anandamayakosam :     -------------------------------  
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI, AZHAL,IYAM)  
A) VALI  
Pranan :   –--------------------- 
Abanan :   ---------------------- 
Samanan :  ----------------------  
Uthanan :   ----------------------  
Vyanan :    ----------------------  
Naagan :     -----------------------  
Koorman :  ----------------------- 
Kirukaran : ----------------------- 
Devathathan :----------------------  
Dhananjayan :---------------------  
 B) AZHAL  
 Analakam:  --------------------  
 Ranjakam :  ---------------------  
 Sathakam :  ---------------------- 
 Prasakam : -----------------------  
 Alosakam : ------------------------ 
 C) IYAM  
Avalambagam:  -------------------------- 
Kilethagam :     ---------------------------  
Pothagam :       --------------------------- 
Tharpagam :    ---------------------------  
Santhigam :      ---------------------------  
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS)  
Saaram :     --------------------  
Senneer :    --------------------  
Oon :           --------------------  
Koluppu :   --------------------- 
Enbu :         --------------------- 
Moolai :      ---------------------  
Sronitham -------------------------  
10. ENVAGAI THERVU:  
I. NAADI: [PULSE PERCEPTION]         II. SPARISAM: [PALPATION]  
III. NAA: [TONGUE]  
 IV.NIRAM: [COMPLEXION]    
 1. Vadham                         2. Pitham                           3. Kabam  
 V.MOZHI: [VOICE]  
1. High Pitched 
 2. Low Pitched  
             3. Medium Pitched 
  
VI. VIZHI: [EYES]  
VII. MALAM: [BOWEL HABITS / STOOLS]  
Niram :    ------------------- 
Irugal :    -------------------- 
Ilagal :     -------------------- 
Others:    -------------------- 
 VIII. MOOTHIRAM [URINE EXAMINATION]    
NEERKKURI:  
Niram :   ---------------------- 
Manam :  --------------------- 
Edai :       ---------------------- 
Nurai:      ---------------------- 




Date:       
Station:  






GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI -600106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI  MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
 FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
 
1. SERIAL NO OF THE CASE:  …………………    
2.OP / IP NO:    ................................    
3. NAME:           ……………………  
 4.AGE:               …………………….   
  5.GENDER:      ................................. 
    
A) BLOOD INVESTIGATIONS:  




              Hb (gm/dL)   
       ESR (mm) 1/2 hr   
 1 hr   






  Lymphocytes            
 Monocytes   
 Eosinophils   
 Basophils   
 
  




BEFORE TREATMENT AFTER TREATMENT  
Albumin   
Sugar   






Date:           
Station:  
 










  GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI - 600106 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI” 
                 FORM V: INFORMED CONSENT FORM 
           “I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I   consent voluntarily to participate my chid in this study and understand that 
I have the   right to withdraw from the study at any time without in any way it affecting 
my chid further medical care”.  
"I have received a copy of the information sheet/consent form".  
Date:  
Signature of the participant:  
In case of illiterate participant  
“I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                    
Date:  
Signature of a witness                                    Left thumb Impression of the Participant      
(Selected by the participant bearing no connection with the survey team)        
Date:     
Station:                                                                                   
Signature of participant:                                                  
 Signature of the Guide:                                   Signature of the Investigator: 
 
அரசு சித்த மருத்துவக் கல்லூரி, சென்னன-106 
       அறிஞர் அண்ணா மருத்துவமனன, சென்னன 
சூலி கணம் ந ாய்க்கான சித்த மரு ்தின் (கண ச ய்)  பரிகரிப்புத் 
திறனனக் கண்டறியும் மருத்துவ ஆய்விற்கான தகவல் படிவம் 
ஒப்புதல் படிவம் ஆய்வாளரால் ொன்றளிக்கப்பட்டது. 
 
            நான் இந்த ஆய்வை குறித்த அவனத்து விபரங்கவையும் நநாயாைிக்கு 
புரியும் ைவகயில் எடுத்துவரத்நதன்  என உறுதியைிக்கிநேன். 
நததி :                                                                         வகயயாப்பம் : 
இடம் :                                                                         யபயர ்   : 
 
நநாயாைியின் யபே்நோர ்ஒப்புதல் படிைம் 
           என்னிடம் இந்த மருத்துை ஆய்வின் காரணத்வதயும், மருந்தின் தன்வம 
மே்றும் மருத்துை ைழிமுவே பே்றியும், யதாடரந்்து எனது உடல் இயக்கத்வத 
கண்காணிக்கவும், அதவன பாதுகாக்கவும் பயன்படும் மருத்துை ஆய்வுக்கூட 
பரிந ாதவனகை் பே்றி திருப்தி அைிக்கும் ைவகயில் ஆய்வு மருத்துைரால் 
விைக்கிக் கூேப்பட்டது.    
            நான் எனது குழந்வதயின் இந்த மருத்துை ஆய்வின் நபாது காரணம் 
எதுவும் கூோமல், எப்யபாழுது நைண்டுமானாலும் இந்த ஆய்விலிருந்து எனது 
குழந்வதவய விடுவித்து யகாை்ளும் உரிவமவய யதரிந்திருக்கிநேன். நான் 
என்னுவடய சுதந்திரமாக நதரவ்ு ய ய்யும் உரிவமவயக் யகாண்டு 
நநாய்க்கான கண யநய் மருந்தின் பரிகரிப்பு திேவனக் கண்டறியும் மருத்துை 
ஆய்விே்கு என் குழந்வதவய உட்படுத்த ஒப்புதல் அைிக்கிநேன். 
 
நததி :                                                                      வகயயாப்பம் : 
இடம் :                                                                     யபயர ்  : 
 
நததி :                                                                       ாட்சிக்காரர ்வகயயாப்பம்: 





துவேத்தவலைர ்வகயயாப்பம்:              ஆராய் ச்ியாைர ்வகயயாப்பம்:  
 
 
      GOVERNMENT SIDDHA MEDICAL COLLEGE, 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600106 
POST- GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’ 
 
          FORM VI - WITHDRAWAL FORM 
 
SI NO:  
OP / IP NO:                                                
NAME:  
AGE / GENDER :  
DATE OF TRIAL COMMENCEMENT:  
DATE OF WITHDRAWAL FROM TRIAL:  
REASONS FOR WITHDRAWAL:  
▪ Intolerance to the drug and development of adverse reactions during the trial.  
▪ Patients turned unwilling to continue in the course of clinical trial.  
▪ Any other acute illness.  
 
 
Date:           
Station:  
Signature of the Guide                                                 Signature of the Investigator     
  
   
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI - 600106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
FORM VII – PATIENT INFORMATION SHEET 
 
Name of Co-Investigator: D.Jeevitha         Name of the college:  
Govt.SiddhaMedical  College  
 Arumbakkam  
 Chennai-106.  
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL.  
 I, D.Jeevitha, studying M.D (Siddha) at Government Siddha Medical College, 
Chennai, is doing a clinical trial on “SooliKanam” (Childhood Bronchial Asthma) in 
children . It is becoming a most common disease, occurring throughout the world. In 
this regard, I am in need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity and 
no physical, psychological or professional risk is involved by taking part in this study. 
Taking part in this study is voluntary. No compensation will be paid to you for taking 
part in this study.  
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions.  
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
"kana nei"(Internal medicine) 3 – 5 years 1 gm & 6- 12 years 2gm bd for 21 days.  
 The information I am collecting in this study will remain between you and the Co- 
investigator (myself). I will ask you few questions through a questionnaire. I will not 
write your name on this form. I will use a code instead.  
The questionnaire will take approximately 20 minutes of your time.  
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact D.Jeevitha, PG Scholar cum Co- investigator of this 
study, attached to Govt. Siddha Medical College, Chennai-106. You can also contact 















அரசு சித்த மருத்துவக் கல்லூரி, சென்னன-106 
  அறிஞர் அண்ணா மருத்துவமனன, சென்னன 
     சூலி கணம் ந ாய்க்கான சித்த மரு ்தின் ( கண ச ய்)  
பரிகரிப்புத் திறனனக் கண்டறியும் மருத்துவ ஆய்விற்க்கான 
தகவல் படிவம் 
 
ஆராய்ெச்ியாளர் சபயர்: நத. ஜீவிதா, 
நிறுைனத்தின் யபயர:்   அரசு சித்த மருத்துைக் கல்லூரி, அரும்பாக்கம், 
ய ன்வன-106. 
 அரசு சித்த மருத்துைக் கல்லூரியில் பட்டநமே்படிப்பு பயின்று ைரும் 
நான் மருத்துைர ்நத.ஜீவிதா சூலி கணம் என்னும் நநாயில் மருத்துை 
ஆராய் ச்ியில் ஈடுபடட்ுை்நைன். 
  
 இந்த ஆராய் ச்ி  ம்பந்தமாக சில நகை்விகவைக் நகட்கவும், 
நதவையான ஆய்ைகப் பரிந ாதவனக்கு தங்கை் குழந்வதவய உட்படுத்தவும் 
உை்நைன். 
 இந்த ஆராய் ச்ிக்கு தங்கை் விருப்பத்தின் நபரில் உட்படும் பட ்த்தில் 
உை்மருந்தாக கண யநய் , 3 முதல் 5 ையது- 1 கி & 6- 12 ையது ைவர 2 கி, 2 
நைவை (காவல, மாவல) உணவுக்கு பின் 21 நாடக்ை் உடய்காை்ை நைண்டும். 
யைைிநநாயாைரக்ை் 5 நாடக்ளுக்கு ஒரு முவே ைரநைண்டும். 
 இந்த மருந்து சிேப்பாக சூலிகணம் நநாய்க்காக அங்கீகரிக்கப்பட்ட 
சித்த மருத்துை நூலில் கூேப்படட்ுை்ைது. 
இந்த ஆராய் ச்ியில் தங்கவை அனுமதித்த பிேகு உங்களுக்கு விருப்பம் 
இல்வலயயனில் எப்நபாது நைண்டுமானாலும் ஆராய் ச்ியில் இருந்து விலகிக் 
யகாை்ை உரிவம உை்ைது. 
 இந்த ஆராய் ச்ிக்கு  ம்பந்தமாக நநாயின் தன்வன பே்றியும் மே்ே 
விபரங்களுக்கும் ஆராய் ச்ியாைர ்மருத்துைர ்நத.ஜீவிதா (பட்டநமே் 
படிப்பாைர,் குழந்வத மருத்துைத் துவே) அைரக்வை எந்த நநரத்திலும் 
யதாடரப்ு யகாை்ைலாம். வகப்நபசி எண்: 9710313354. 
 
 நமலும் இந்த ஆராய் ச்ிக்கு தக்க அனுமதி  ் ான்று யபேப்படட்ுை்ைது. 
 இந்த மருந்து முே்றிலும் பாதுகாப்பான மூலிவக யபாருட்கவைக் 
யகாண்டு தயாரிக்கப்படட்ுை்ைது. பக்க விவைவுகவை ஏே்படுத்தாது. நமலும் 
உணவு முவேயில் மருத்துைரால் கூேப்படும் பத்தியம் காக்குமாறு 
அறிவுறுத்தப்படுகிேது. 
 இது  ம்பந்தமான தங்கைது அவனத்து விைரங்களும் ரகசியமாக 
வைக்கப்படும் என உறுதி அைிக்கிநேன். 
 இதில் பயணப்படி முதலிய எந்த உதவித் யதாவகயும் ைழங்கப்பட 
மாட்டாது. 
 இந்த ஆராய் ச்ியின் நபாது உடலுக்கு நைறு பாதிப்பு ஏே்படும் 

















  GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
          CHENNAI -600106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
  AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
FORM X - ADVERSE REACTION REPORTING FORM 
 
SERIAL NO:    ………………                                                                                                        
OP/IP NO:         ...…………….. 
NAME:              ……………….                     
AGE:                  ……………….                           
 GENDER:          ………………. 
DATE OF TRIAL COMMENCEMENT:  
DATE  OF OCCURRENCE OF THE ADVERSE REACTION:           TIME:  





Date:                                                                               
Station:  
Signature of the Guide                                                 Signature of the Investigator    
 
 
  XI.CASE SHEET PROFORMA 
                   GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                             CHENNAI-600106 
POST- GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL ST UDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDREN WITH THE EVALUATION OF 
SIDDHA TRIAL DRUG ‘KANA NEI’’ 
 
       Branch -IV KUZHANTHAI MARUTHUVAM 
 
PROFORMA OF CASE SHEET FOR KANAM  
IP. No :           Nationality  :  
Name  :           Religion  :  
Age  :           Date of Admission :  
Sex  :           Date of Discharge :  
Address  :          Diagnosis  :  
Informant :            Medical Officer :  
1. Complaints and duration   :     
2. History of present illness   :     
3. History of previous illness  :     
4. Antenatal history   :      
5. Birth history    :     
6. Neonatal history   :    
 7. Development history   :  
8. Nutritional  history   :  
9. Socio environmental history  :  
10. Family history    :  
11. Immunization history   :  
 Clinical examination General examination  
1. Consciousness   :  
2. Stature    : 
 a. Height   :  
b. Weight   : 
 c. Head circumference :   
d. Mid arm circumference :  
    e. Chest circumference :   
 3. Nourishment   :  
4. Anaemia    :  
5. Cyanosis    :  
6. Clubbing    :  
7. Jaundice    :  
8. Lymphadenopathy   :  
9. Abdominal distension  :  
10. Pedal oedema   : 
Vital Sign  
1. Temperature  :  
2. Pulse rate  :  
3. Respiratory rate :  
4. Heart rate  :  
5. Blood pressure  :  
  
Siddha aspect : 
 Nilam : 
1. Kurinji  :  
2. Muilai  :  
3. Marutham  :  
4. Neithal  :  
5. Palai   : 
 Parvakalam :  
1. Kaar   :  
2. Koothir   :  
3. Munpani  :  
4. Pinpani   : 
5. Elavenil   :  
6. Muthuvenil  :  
Poripulangal  :  
1. Mei  :  
2. Vai   :  
3. Kan  :  
4. Mooku  :  
5. Sevi  :  
Kanmenthiriyam :  
1. Kai  :   
2. Kaal  :  
3. Vaai  :  
4. Eruvai  : 
5. Karuvai  :  
Uyirthathukkal : 
Vadham : 
1. Praanan   :  
2. Abaanan   :  
3. Viyaanan   :  
4. Uthaanan   :  
5. Samaanan   : 
6. Nagan   :  
7. Koorman   :  
8. Kirukaran   :  
9. Devathatthan  :  
10.   Dhananjeyan  :  
Pitham : 
1. Anal Pitham  :  
2. Ranjagam   :  
3. Saadhagam  :  
4. Praasagam   :  
5. Aalosagam   :  
Kabam : 
1. Avalambagam  :  
2. Kilethagam  :  
3. Pothagam  :  
4. Tharpagam  :  
5. Santheegam  :  
Udarkattugal :  
1. Saaram   :  
2. Senneer  :  
3. Oonn   :  
4. Kozhuppu  :  
5. Enbu   :  
6. Moolai   :  
7. Sukkilam / Suronitham:      Not applicable  
Ennvagaithervugal : 
1. Naadi   :  
2. Naa   :  
3. Niram   :  
4. Mozhi   :  
5. Vizhi   :  
6. Sparisam  :  
7. Malam   :  
8. Moothiram  :  
 Modern Aspects   
Respiratory System : 
1. Inspection  :  
2. Palpation  :  
3. Percussion  :  
4. Auscultation  :  
Examination of other system :  
Cardiovascular system   
Abdomen  
Central nervous system  
Laboratory investigations : 
Blood : 
TC    :  
DC    :  
ESR   :  
1/2hr,  :  
1 hr  :  
Hb%  :  
Urine : 
  Albumin   :  
  Sugar    :  
Deposit  :  
 Stools : 
Ova   :   
Cyst   :  
Other Investigations :  
X-ray- chest PA view:   
Mx test  :  
 
Investigation - Siddha aspect :  
Neerkuri and Neikuri :  
1. Neerkuri : 
Niram   :  
Edai   :  
Manam  :  
Nurai   :  
Enjal   :  
2. Neikuri Daily progress : 
 
DATE SYMPTOMS MEDICINE 
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